


Stereoselective Synthesis of 2,3-Diamino-2,3-dideoxy- β -D-mannopyranosyl Uronates

Marthe T. C. Walvoort, Gert-Jan Moggré, Gerrit Lodder, Herman S. Overkleeft, Jeroen D. C. Codée,* and Gijsbert A. van der Marel*

Leiden Institute of Chemistry, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands

S Supporting Information

ABSTRACT: With the aim to find an efficient synthetic procedure for the construction of 2,3-diamino-2,3-dideoxy- β -D-mannuronic acids, we evaluated three mannopyranosyl donors: (*S*)-phenyl 4,6-di-*O*-acetyl-2,3-diazido mannopyranoside, (*S*)-phenyl 2,3-diazido-4,6-*O*-benzylidene mannopyranoside, and (*S*)-phenyl 2,3-diazido mannopyranosyl methyl uronate. The first two mannopyranosylating agents are rather unselective or slightly α -selective in their condensation with three different acceptors. The mannanuronic acid donor on the other hand reliably provides the desired β -mannosidic linkage. A mechanistic rationale is put forward to account for the different behavior of the three donor types. Suitably protected 2,3-diazido mannanuronic acids were employed to construct the all-*cis*-linked tetrasaccharide repeating unit of the capsular polysaccharide of *Bacillus stearothermophilus*, featuring two 2,3-diacetamido-2,3-dideoxy- β -D-mannuronic acids.



INTRODUCTION

Functional groups on a glycosyl donor play a decisive role on the stereochemical course of its glycosylation reactions. In our studies toward the synthesis of anionic (bacterial) oligosaccharides, we have recently disclosed that glycosylations of mannanuronic acid ester donors, that is, mannopyranosides of which the C-6 is oxidized to a carboxylic acid ester, such as **1** (Figure 1), proceed with a very high degree of β -selectivity.¹ Initially, we postulated that the observed β -selectivity was the result of the S_N2 -like reaction of an intermediate α -triflate (**2**), in line with the seminal work of Crich and co-workers on 4,6-*O*-benzylidene directed β -mannosylations.² We reasoned that the C-5 carboxylic ester is sufficiently electron-withdrawing to stabilize the anomeric triflate with respect to the oxocarbenium–triflate ion pair to allow for a β -selective displacement reaction. However, we were at that time unable to spectroscopically detect a single anomeric triflate species. Examination of the activation of a series of 2-azido-2-deoxy mannanuronic acid ester donors, including thiomannoside **3**, revealed that an anomeric triflate was formed from these donors and that it exists as a mixture of 4C_1 and 1C_4 conformers, **4a** and **4b**, respectively, in which the latter species, having an equatorially positioned triflate, surprisingly prevailed.³ Although these studies showed the intermediacy of an anomeric triflate species, the fact that this triflate species prefers to adopt an “inverted” chair conformation lends support to an alternative mechanistic rationale for the β -selectivity which invokes the 3H_4 mannanuronic acid ester oxocarbenium ion **5** as the product forming intermediate (Figure 1).⁴ In line with the detailed studies of Woerpel and co-workers on the stereochemical alkylation of oxocarbenium ions,⁵ this intermediate is preferentially attacked by an incoming nucleophile from the β -face,




Figure 1. Mannopyranosyl uronic esters studied previously.

explaining the observed β -selectivity. It was reasoned that the C-5 carboxylate was at the basis of this unusual conformational behavior. It also became apparent in our studies of the C-2 azido mannanuronic acid series that the introduction of the C-2 azido functionality in **3** did not significantly alter the β -selectivity of the glycosylation reaction with respect to the glycosylations of its C-2 benzyloxy counterpart **1**.^{3b} Notably, this contrasts with the 4,6-*O*-benzylidene β -mannosylation system in which the selectivity has been shown to be sensitive to the nature of the C-2 substituent.⁶ Work from our laboratory has revealed that condensations involving 2-azido-2-deoxy-4,6-*O*-benzylidene mannopyranosyl donors proceed somewhat less β -selective than couplings with its C-2-*O*-benzyl counterpart.⁷ To further investigate the influence of different substitution patterns on glycosylation with mannopyranosyl and mannanuronic acid ester donors, we here report the results

Received: June 7, 2011

Published: July 27, 2011

of our study of 2,3-diaziido-2,3-dideoxy mannopyranosyl⁸ and mannopyranosyl uronate donors. 2,3-Diacetamido-dideoxy mannopyranosyl uronates are found in various bacterial capsular polysaccharides,⁹ in which they are usually linked in a 1,2-*cis* fashion to the next sugar residue. An efficient route of synthesis toward these rare bacterial carbohydrates can help to elucidate their role in biology and immunology. We also report the stereoselective assembly of the tetrasaccharide repeating unit of the capsular polysaccharide of *Bacillus stearothermophilus*, containing two 2,3-diacetamido-2,3-dideoxy- β -mannopyranosyl uronates (**47**, Scheme 2).¹⁰


RESULTS AND DISCUSSION

We investigated three types of 2,3-diaziido mannosyl donors, the 4,6-di-*O*-acetyl mannosides **6 α** and **6 β** , the 4,6-*O*-benzylidene mannoside **7**, and the mannuronic acid esters **8 α** and **8 β** (Scheme 1). The first two donors were selected because we previously reported that the installment of electron-withdrawing groups such as an *O*-acetate on C-4 and C-6 of a 2-azido mannosyl donor also provides β -selective condensation reactions, depending on the nature of the acceptor used.¹¹ More recently, Kim and co-workers reported on the stereodirecting effect of electron-withdrawing groups at C-3, C-4, and C-6 in mannosylations.¹² Donors **6**, **7**, and **8** were synthesized as depicted in Scheme 1. Key intermediate **13**

was obtained following an adaptation of the procedure described by Guthrie and Murphy.¹³ Starting from 4,6-*O*-benzylidene-protected methyl glucoside **9**,¹⁴ double methanesulfonylation toward compound **10** and subsequent epoxidation using potassium hydroxide in THF/MeOH resulted in crystalline compound **11** in 62% over two steps. Selective *trans*-diaxial opening of the epoxide with sodium azide in DMF at reflux temperature gave 2-azido-2-deoxy-atropyranoside **12** in 93%.

Subsequent triflation of C-3-OH and S_N2 substitution with NaN₃ in DMF at 80 °C resulted in diaziido-containing mannopyranoside **13** via inversion of configuration at C-3.¹⁵ In one step, the benzylidene and anomeric methyl function were hydrolyzed with concomitant acetylation of the liberated alcohols to afford compound **14** as an anomeric mixture ($\alpha/\beta = 5:1$). Treatment of compound **14** with PhSH and BF₃·Et₂O in DCE at 50 °C resulted in α -thio donor **6 α** (24%) and β -thio donor **6 β** (58%), which were readily separated. Subsequent deacetylation under Zemplén conditions gave diols **15 α/β** . Crystalline benzylidene donor **7** was obtained from diol **15 β** using benzaldehyde dimethylacetal and a catalytic amount of *p*-TsOH in 69% yield. To obtain the mannuronic acid donors **8 α/β** , diols **15 α/β** were subjected to regio- and chemoselective oxidation at C-6 using the TEMPO/BAIB reagent combination.^{16,17} From diol **15 α** , compound **16 α** was obtained in 76% yield after oxidation and ensuing methylation. Under similar conditions, diol **15 β**

Scheme 1. Synthesis of Donors **6**–**8 α**



^a Reagents and conditions: (a) MsCl, pyridine; (b) KOH, THF/MeOH (**11**, 62% over two steps); (c) NaN₃, NH₄Cl, DMSO, 80 °C (**12**, 93%); (d) (i) Tf₂O, pyridine; (ii) NaN₃, NH₄Cl, DMF, 80 °C (**13**, 75%); (e) H₂SO₄, Ac₂O (**14**, 98%); (f) PhSH, BF₃·Et₂O, DCE, 50 °C (**6 α** , 24%; **6 β** , 58%); (g) NaOMe, MeOH (**15 α** , 100%; **15 β** , 98%); (h) PhCH(OMe)₂, *p*-TsOH, MeCN (**7**, 69%); (i) (i) TEMPO, BAIB, DCM/H₂O; (ii) MeI, K₂CO₃, DMF (**16 α** , 76%); (j) Ac₂O, pyridine (**8 α** , 91%; **8 β** , 100%); (k) (i) TEMPO, BAIB, EtOAc/H₂O; (ii) MeI, K₂CO₃, DMF (**16 β** , 91%).




Figure 2. Overview of mannopyranosyl triflates.


transformed into **16 β** in a somewhat lower yield (50%). Changing the organic solvent of the biphasic oxidation mixture from dichloromethane to ethyl acetate, in which the crystalline **15 β** proved to be more soluble, led to an increased yield (91%) of compound **16 β** . Methyl manuronates **16 α** and **16 β** were acetylated using Ac₂O in pyridine to give donors **8 α** and **8 β** .







With the five donors, **6 α/β** , **7**, and **8 α/β** , in hand, we first investigated their activation in low-temperature NMR experiments. Upon treatment of diacyl donor **6 β** with Ph₂SO and Tf₂O^{18,19} in DCM-*d*₂ at $-80\text{ }^{\circ}\text{C}$, α -triflate **17** was rapidly formed (see Figure 2). This species proved to be stable to $+10\text{ }^{\circ}\text{C}$. α -Configured donor **6 α** provided the same triflate but required a higher temperature for complete activation ($-40\text{ }^{\circ}\text{C}$). Using the same activator system,²⁰ benzylidene donor **7** was rapidly transformed at $-80\text{ }^{\circ}\text{C}$ into α -triflate **18**, which was stable up to $0\text{ }^{\circ}\text{C}$. Similarly, β -diazido mannonic acid donor **8 β** was completely transformed into the corresponding anomeric triflate **19** at $-80\text{ }^{\circ}\text{C}$. In analogy to the monoazido mannonic acid triflate **4**, this species exists as a mixture of ⁴C₁ and ¹C₄ conformers (⁴C₁/¹C₄ \sim 4.5:1). Decomposition of this triflate started around $-10\text{ }^{\circ}\text{C}$, making this species the least stable of the three diazido mannonic triflates, in contrast to what could be expected based on the electron-withdrawing capacity of the different functional groups. The result is in line, however, with the relatively low decomposition temperatures for mannonic acid triflates **2** and **4**, as depicted in Figure 2.³ From the decomposition temperatures of the three different mannonates, **2**, **4**, and **19**, it is clear that the extra C-3 azide group in **19** has a stabilizing effect, as expected on the basis of its electron-withdrawing capacity (*F* value \sim 0.48).²¹ The last donor in the series, α -mannuronic acid **8 α** , required a significantly higher temperature ($-10\text{ }^{\circ}\text{C}$) for complete activation than its β -configured counterpart. As in the case of the monoazido mannonic acid **3**, the temperature required for complete activation of the α -isomer **8 α** matched the decomposition temperature of the anomeric triflate.

Next, β -thio donors **6 β** , **7**, and **8 β** were surveyed in a set of glycosylation reactions with primary acceptor **20** and secondary acceptors **21** and **22**. To this end, the donors were preactivated (Ph₂SO–Tf₂O) for 20 min at $-80\text{ }^{\circ}\text{C}$ before the addition of the acceptor alcohols and warming to $0\text{ }^{\circ}\text{C}$. The results of the condensations are summarized in Table 1. As can be seen from

entries 1–3, the condensations with diacetyl diazido mannoside **6 β** proceeded with very little selectivity. Entries 4–6 show that the benzylidene donor **7** is moderately α -selective. Clearly, these results oppose the results obtained with 2,3-di-*O*-benzyl benzylidene mannosyl donors and found them to be moderately β -selective. More recently, Crich and co-workers have reported on the condensations of an α -(*S*)-phenyl 3-azido-2-*O*-benzyl-4,6-*O*-alkylidene mannopyranosyl donor,²² which also proceed with moderate β -selectivity. The substitution of a single *O*-benzyl group for an azide functionality thus already causes a drop in selectivity. The introduction of two azides leads to further erosion of β -selectivity, providing moderate α -selectivity in two of the three cases studied here. Crich and co-workers have rationalized the erosion of β -selectivity, observed with small substituents at the C-2 or C-3 position, through the observation that formation of the benzylidene mannosyl ⁴H₃ oxacarbenium ion from the corresponding α -triflate proceeds with concomitant compression of the R2–C-2–C-3–R3 torsion angle, which is easier if the substituents R2 and R3 are smaller.^{6a,23} The diazido case studied here supports this mechanistic rationale: the presence of the two small azides (*A* value \sim 0.45–0.62 kcal mol⁻¹)²⁴ allows the mannosyl triflate to readily collapse into the α -selective ⁴H₃ oxacarbenium ion. It should be noted that the electron-withdrawing effect of the azide does not counterbalance this steric effect, which has also been found for C-3-*O*-benzyl-C-2-fluoro- and C-2-*O*-benzyl-C-3-fluorobenzylidene mannosides.^{6a} A similar rationale can account for the poor selectivity obtained with donor **6 β** . Furthermore, Kim and co-workers have argued that participation of a remote C-6-*O*-acetate can also account for the formation of α -linked products from otherwise benzylated mannosides.¹² In the present case, we cannot exclude such a mechanism to contribute to the formation of the α -mannosides.

Entries 7–9 show that the three diazido mannonate disaccharides **29**, **30**, and **31** were all formed in a β -selective fashion. Secondary alcohol **21** gave the poorest selectivity and yield in the series, which parallels the results of condensations of this acceptor with other mannonate donors.^{3a} Introduction of two azides on the mannonic acid core thus has little influence on the selectivity of the mannonic acid type donors, in contrast to the other two types of donors studied here. A possible explanation for this

Table 1. Glycosylation Study of Donors **6β**, **7**, and **8β**^a


Entry	Donor	Acceptor	Product	Ratio α : β	Yield (%)
1		20	23	1 : 1	75
2		21	24	2 : 1	45
3	6β	22	25	2.5 : 1	66
4		20	26	3 : 1	79
5		21	27	5 : 1	66
6	7	22	28	1 : 1	81
7		20	29	1 : 5.5	94
8		21	30	1 : 3.5	49
9	8β	22	31	1 : 7.5	89

^a Conditions: donor **6β** or **7**, Tf₂O (1.3 equiv), Ph₂SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05) at -80°C , then add acceptor (1.5 equiv). Donor **8β**, Tf₂O (1.3 equiv), Ph₂SO (1.3 equiv), TTBP (2.5 equiv), DCM (0.05) at $-80 \rightarrow -60^{\circ}\text{C}$, then add acceptor (1.5 equiv).





Figure 3. 2,3-Diazido manuronate oxocarbenium ions.

observation can be found in the preferred conformation of the manuronate oxocarbenium ions, in which the C-5 carboxylic acid ester prefers to occupy a pseudoaxial position (as in **5**, Figure 1), making the ³H₄ oxocarbenium ion energetically favored over its ⁴H₃ counterpart. Nucleophilic attack at the ³H₄ oxocarbenium ion leads to the preferential formation of the β-product. Woerpel and co-workers have established that an azido group follows the preference of an O-alkyl substituent to occupy an axial orientation in an oxocarbenium ion intermediate.^{5a} The relative stabilities of the diazido manuronate ³H₄ and ⁴H₃ oxocarbenium ions **32** and **33** thus mirror those of the 2,3-di-O-benzyl manuronate, making the former favored over the latter and providing a positive contribution to the formation of the β-linked product (Figure 3). The same line of reasoning can be applied to a product forming exploded transition state (**34**) in which the triflate dissociates from the diazido manuronate core leading to partial oxocarbenium ion character at C-1, which is best accommodated in a ³H₄-like conformation. S_N2-like reaction of this species provides the β-linked product. Although it could be reasoned that installment of two azides and the C-5 carboxylic acid ester would provide a highly disarmed donor, which would be difficult to activate, the yields obtained in the condensations of donor **8β** with alcohols **20** and **22** clearly show this not to be the case: the donors can be activated at temperatures as low as -80°C to provide reactive glycosylating species. The conformational behavior of the manuronates could be at the basis of this unexpected reactivity.²⁵

Having established that the diazido manuronate donor **8β** is the donor of choice for the introduction of the 2,3-diamino-2,3-dideoxy β-mannosidic bond, we sought to explore its utility in the construction of a complex oligosaccharide. To this end, we selected the repeating unit of the secondary cell wall polysaccharide of *Bacillus stearothermophilus*, [→4)-β-D-ManpA2,3(NAc)₂-(1→6)-α-D-Glcp-(1→4)-β-D-ManpA2,3(NAc)₂-(1→3)-α-D-GlcpNAc-(1→)]_n,⁹ as a synthetic target (Scheme 2). This all-*cis*-linked oligosaccharide features two β-linked diacetamino manuronate acids in addition to an α-glucose and an α-glucosamine moiety. We decided to construct tetrasaccharide **47**, having an aminopentanol spacer at its reducing end, from three building blocks: reducing end glucosamine **39**, glucose manuronate disaccharide **41**, and terminal manuronate **44**. We based our synthesis on the use of the central disaccharide **41** because this type of disaccharide performed well in the construction of *Micrococcus luteus* oligomers, composed of repeating [→6)-α-D-Glcp-(1→4)-β-D-ManpA2(NAc)-(1→)]_n units.^{3b} The synthesis of these building blocks and the full assembly of the tetrasaccharide is depicted in Scheme 2. The synthesis of acceptor **39** started from hemiacetal **35**,^{26a,b} which was transformed into *N*-phenyltrifluoroacetimidate **36**^{26c} in 96% yield. The stereoselective condensation of this donor with *N*-(benzyl)benzyloxycarbonyl-5-aminopentanol required some optimization. When a mixture of **36** and the acceptor in DCM was treated with a catalytic amount of TfOH at 0°C , compound **37** was formed as an α/β mixture, with a slight preference for the α-anomer. The addition of thiophene to the reaction mixture as prescribed by Boons et al.²⁷ to enhance the α-selectivity did not result in a better selectivity. By using diethyl ether as the solvent and lowering the reaction temperature to -40°C , the stereoselectivity of the reaction was enhanced to provide product **37** in 77% yield and a 7:1 α/β ratio. Separation of the two anomers was troublesome at this stage, and therefore, **37** was transformed into alcohol **39** by subsequent deacetylation and silylidene formation. After this sequence of reactions, pure α-configured acceptor **39**

Scheme 2. Construction of Tetrasaccharide 47^a

^a Reagents and conditions: (a) C(NPh)CF₃-Cl, K₂CO₃, acetone/H₂O (96%, $\alpha/\beta = 1.4:1$); (b) *N*-(benzyl)benzyloxycarbonyl-5-aminopentanol, TfOH (cat.), Et₂O, -40 \rightarrow -10 $^{\circ}\text{C}$ (77%, $\alpha/\beta = 7:1$); (c) NaOMe, MeOH (quant.); (d) (tBu)₂Si(OTf)₂, DMF (76%); (e) **40**, **16 β** , TfOH (cat.), Et₂O, -40 \rightarrow -10 $^{\circ}\text{C}$ (96%); (f) **41**, Ph₂SO, Tf₂O, DCM, -80 \rightarrow -60 $^{\circ}\text{C}$, then **39**, -80 \rightarrow -10 $^{\circ}\text{C}$ (99%); (g) Et₃N, pyridine (94%); (h) TBSOTf, Et₃N, DCM, (88%); (i) **44**, Ph₂SO, Tf₂O, TTBP, DCM, -80 $^{\circ}\text{C}$, then **43**, -30 $^{\circ}\text{C}$ overnight, (74%); (j) (i) TBAF, HOAc (96%); (ii) TBAF, HOAc (75%); (k) KOH, H₂O₂, THF, H₂O; (l) (i) Zn, AcOH, THF; (ii) Ac₂O, NaHCO₃, THF, H₂O; (m) H₂, Pd/C, H₂O, THF, HCl (20%).

could be isolated in 76% yield. The disaccharide **41** was constructed using 6-*O*-Fmoc-protected glucose imidate donor **40** and (*S*)-phenyl diazido mannanuronic acid **16 β** using conditions we previously established for the α -selective condensation of **40** and the monoazido mannanuronic acid counterpart of **16 β** .^{3b,28} The key disaccharide **41** was obtained in excellent yield as a single anomer. Next, dimer **41** and glucosamine **39** were fused using our standard Ph₂SO-Tf₂O preactivation protocol in the absence of any base to prevent undesired Fmoc cleavage. All-*cis*-linked trisaccharide **42** was obtained in near quantitative yield as a single diastereomer, highlighting the apt glycosylating capacity of the diazido mannanuronic acid donor. Liberation of the 6''-OH under mild basic conditions then set the stage for the final coupling, in which the trisaccharide acceptor **43** was condensed with C-4-*O*-TBS-protected diazido mannanuronic acid **44**, obtained from **16 β**

by treatment with TBSOTf and Et₃N in 88% yield. The stereochemical outcome of this reaction did not pose any problems, but to obtain a profitable yield, some experimentation was required. After trying different reaction temperatures and times, the best conditions (reaction at -30 $^{\circ}\text{C}$ overnight) provided the fully protected tetrasaccharide **45** in 74% yield. It is of interest to note that the replacement of the electron-withdrawing C-4-*O*-acetyl in **8 β** by the less electron poor TBS ether in **44** does not adversely affect the β -selectivity of the diazido mannanuronic acid donor.

Deprotection of the tetrasaccharide started with the removal of the silyl groups. It was found that the silylidene group could be removed without affecting the C-4'''-*O*-TBS ether.²⁹ In fact, removal of this latter silyl ether was extremely sluggish and deprotection of the C-4'''-OH required 72 h for completion. Next, the carboxylic acid esters were saponified using KOH in H₂O/THF to

provide the diacid. Initially, we tried to simultaneously reduce the five azide groups and benzyl ethers and benzylcarbonate functionality under Birch conditions.^{3b} Unfortunately, this led to partial fragmentation of the oligosaccharide through cleavage of the β -mannuronic acid bonds, a side reaction we have also observed in our synthesis of *M. luteus* [$\rightarrow 6$]- α -D-Glcp-(1 \rightarrow 4)- β -D-ManpA2(NAc)-(1 \rightarrow)_n oligomers. We therefore resorted to a stepwise reduction procedure, in which first the four azides were reduced using zinc in acetic acid,³⁰ followed by aqueous acetylation of the liberated amines. Removal of the benzyl ethers and benzyloxycarbonyl groups by treatment with H₂ over Pd/C in the presence of aqueous HCl completed the synthesis of the target tetrasaccharide. The fully deprotected tetramer **47** was purified by HPLC and isolated in 20% overall yield.

CONCLUSIONS

Three different 2,3-diazido-2,3-dideoxy mannosylating agents were evaluated for their potential to provide β -mannosidic bonds: the 4,6-di-O-acetyl- and 4,6-O-benzylidene-2,3-diazido-2,3-dideoxy mannosylating donors proved to be rather unselective or slightly α -selective. In contrast, 2,3-diazido-2,3-dideoxy mannuronic acid esters provided the desired β -linked product with good selectivity. The observed differences in stereochemical outcome suggest that different mechanistic pathways take place: the 4,6-di-O-acetyl- and 4,6-O-benzylidene systems react through an α -selective ⁴H₃-oxocarbenium ion-type intermediate (or corresponding transition state), while the reactions of the mannuronate donors involve a transition state with ³H₄ oxocarbenium ion-like character. The profitable β -mannosylating properties of the diazido mannuronates were exploited in the stereoselective synthesis of an all-*cis*-linked *Bacillus stearothermophilus* tetrasaccharide, featuring two β -mannuronic acid linkages. It is expected that the methodology described here can be readily applied in the synthesis of diamino mannuronic acid containing polysaccharides of different bacteria,³¹ such as *Bordetella pertussis*, *Pseudomonas aeruginosa*, and *Neisseria meningitidis*. Current research is aimed at further unravelling the reaction mechanism(s) underlying the β -selectivity and reactivity of mannuronic acids.

EXPERIMENTAL SECTION

General Procedure for the Low-Temperature NMR Experiments. A mixture of the donor (30 μ mol) and Ph₂SO (39 μ mol)²⁰ was coevaporated with toluene (2 \times). The residue was dissolved in DCM-d₂ (0.6 mL) and transferred to an NMR tube under an argon atmosphere. The tube was stoppered and sealed. The NMR magnet was cooled to -80 °C, locked, and shimmed. In an acetone bath (-80 °C), the sample was treated with Tf₂O (39 μ mol), shaken three times, and placed back in the NMR magnet. The first ¹H spectrum was immediately recorded. Further temperature changes were executed depending on the spectra recorded but always with multiples of 10 °C.

General Procedure for the Ph₂SO/Tf₂O-Mediated Glycosylations. A mixture of the donor (1 equiv), Ph₂SO (1.3 equiv), and TTBP (2.5 equiv) was coevaporated twice with toluene. While the mixture was under an argon atmosphere, freshly distilled DCM (0.05 M) was added, followed by the addition of activated molecular sieves (3 Å). The resulting mixture was stirred for 30 min at room temperature and cooled to the activation temperature. Tf₂O (1.3 equiv) was added in one portion, and the activation progress was monitored by TLC analysis. In the case of uronic acid donor **8 β** , the temperature was raised to -60 °C in 20 min and cooled back to -80 °C. Then a solution of the acceptor (0.3–0.5 M in DCM) was slowly added via the wall of the flask. The mixture was

allowed to warm to 0 °C, after which Et₃N or pyridine was added to quench the reaction. Aqueous workup, passage of the residue through a column of Sephadex LH-20 (eluted with DCM/MeOH, 1/1, v/v), and purification using flash column chromatography (silica gel) gave the coupled product.

Phenyl 4,6-Di-O-acetyl-2,3-diazido-2,3-dideoxy-1-thio- α / β -D-mannopyranoside (6 α /6 β). Compound **14** (0.39 g, 1.08 mmol) and PhSH (0.13 mL, 1.25 mmol) were dissolved in DCE (5.65 mL), followed by the addition of BF₃·Et₂O (0.28 mL, 2.26 mmol), and the solution was heated to 50 °C (5 h). Saturated aqueous NaHCO₃ was added, and the mixture was diluted with EtOAc. The organic layer was washed with H₂O (2 \times). Purification using column chromatography (silica gel, 20% EtOAc in PE for the α -anomer, 25% EtOAc in PE for the β -anomer) yielded the pure anomers **6 α** and **6 β** as off-white amorphous solids (0.36 g, 0.89 mmol, 82%, α/β = 1:2.4). TLC R_f α -anomer 0.50, β -anomer 0.34 (PE/EtOAc, 2/1, v/v). spectroscopic data for the α -anomer: [α]_D²⁰ +110.0 (c 1, DCM); IR (neat, cm⁻¹) 1034, 1227, 1728, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.45–7.51 (m, 2H, CH_{arom}), 7.32–7.36 (m, 3H, CH_{arom}), 5.54 (d, 1H, J = 1.0 Hz, H-1), 5.31 (t, 1H, J = 9.9 Hz, H-4), 4.44 (ddd, 1H, J = 2.4, 5.6, 9.8 Hz, H-5), 4.23 (dd, 1H, J = 5.6, 12.3 Hz, H-6), 4.16 (dd, 1H, J = 1.3, 3.5 Hz, H-2), 4.09 (dd, 1H, J = 2.4, 12.3 Hz, H-6), 4.00 (dd, 1H, J = 3.5, 10.0 Hz, H-3), 2.16 (s, 3H, CH₃ Ac), 2.05 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.3, 169.2 (C=O Ac), 131.9 (C_q SPh), 131.9, 129.1, 128.2 (CH_{arom}), 85.5 (C-1), 69.4 (C-5), 67.2 (C-4), 63.3 (C-2), 62.0 (C-6), 60.7 (C-3), 20.4, 20.4 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 85.5 (J_{C1,H1} = 169 Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₁₆H₂₂N₇O₅S 424.13976, found 424.13994. Spectroscopic data for the β -anomer: [α]_D²⁰ +14.4 (c 1, DCM); IR (neat, cm⁻¹) 1034, 1211, 1736, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.50–7.55 (m, 2H, CH_{arom}), 7.30–7.34 (m, 3H, CH_{arom}), 5.27 (t, 1H, J = 10.0 Hz, H-4), 4.83 (d, 1H, J = 1.4 Hz, H-1), 4.21 (dd, 1H, J = 6.1, 12.2 Hz, H-6), 4.13–4.17 (m, 2H, H-2, H-6), 3.80 (dd, 1H, J = 3.7, 10.0 Hz, H-3), 3.60 (ddd, 1H, J = 2.8, 6.0, 9.6 Hz, H-5), 2.13 (s, 3H, CH₃ Ac), 2.08 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.0, 169.2 (C=O Ac), 132.9 (C_q SPh), 131.1, 128.8, 127.7 (CH_{arom}), 86.1 (C-1), 76.3 (C-5), 66.8 (C-4), 64.0 (C-2), 63.8 (C-3), 62.2 (C-6), 20.2, 20.2 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 86.1 (J_{C1,H1} = 155 Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₁₆H₂₂N₇O₅S 424.13976, found 424.13984.

Phenyl 2,3-diazido-4,6-O-benzylidene-2,3-dideoxy-1-thio- β -D-mannopyranoside (7). To a solution of compound **15 β** (0.38 g, 1.18 mmol) in dry acetonitrile (9 mL) were added PhCH(OMe)₂ (0.33 mL, 2.2 mmol) and *p*-TsOH (cat). The resulting solution was stirred overnight at rt, followed by the addition of Et₃N until pH was almost neutral. EtOAc was added, and the solution was washed with saturated aqueous NaCl (2 \times), dried over Na₂SO₄, and concentrated in vacuo. The title compound was obtained by crystallization from EtOAc/PE as white fluffy crystals (0.33 g, 0.81 mmol, 69%): TLC R_f 0.52 (PE/EtOAc, 4/1, v/v); [α]_D²⁰ +34.4 (c 1, DCM); melting point = 178–180 °C; IR (neat, cm⁻¹) 696, 978, 1078, 1096, 1263, 2099, 2151; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.44–7.53 (m, 4H, CH_{arom}), 7.31–7.42 (m, 6H, CH_{arom}), 5.66 (s, 1H, CH Ph), 4.90 (s, 1H, H-1), 4.35 (dd, 1H, J = 4.9, 10.6 Hz, H-6), 4.09–4.20 (m, 2H, H-2, H-4), 3.87–3.96 (m, 2H, H-3, H-6), 3.47 (dt, 1H, J = 4.9, 9.5, 9.7 Hz, H-5); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 136.6 (C_q Ph), 133.2 (C_q SPh), 132.0, 129.3, 129.1, 128.3, 125.8 (CH_{arom}), 101.6 (CH Ph), 87.5 (C-1), 76.9 (C-4), 72.0 (C-5), 68.3 (C-6), 64.9 (C-2), 63.1 (C-3); ¹³C-GATED (CDCl₃, 100 MHz) δ 87.5 (J_{C1,H1} = 157 Hz, C-1); HRMS [M + H]⁺ calcd for C₁₉H₁₉N₆O₃S 411.12339, found 411.12343.

Methyl (Phenyl 4-O-acetyl-2,3-diazido-2,3-dideoxy-1-thio- α -D-mannopyranosyl uronate) (8 α). Compound **16 α** (0.24 g, 0.69 mmol) was treated with Ac₂O/pyridine (6 mL, 1/3, v/v) until TLC analysis indicated complete consumption of the starting material.

The mixture was diluted with EtOAc, washed with H₂O and saturated aqueous NaCl, dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 25% EtOAc in PE) yielded the title compound as yellowish oil (0.25 g, 0.62 mmol, 91%): TLC *R_f* 0.43 (PE/EtOAc, 3/1, v/v); [α]_D²⁰ +70.6 (c 1, DCM); IR (neat, cm⁻¹) 748, 1049, 1211, 1751, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.53–7.58 (m, 2H, CH_{arom}), 7.30–7.36 (m, 3H, CH_{arom}), 5.55 (d, 1H, *J* = 5.1 Hz, H-1), 5.42 (t, 1H, *J* = 6.8 Hz, H-4), 4.65 (d, 1H, *J* = 6.5 Hz, H-5), 4.06 (dd, 1H, *J* = 3.4, 7.4 Hz, H-3), 4.00 (dd, 1H, *J* = 3.6, 4.9 Hz, H-2), 3.76 (s, 3H, CH₃ CO₂Me), 2.12 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 169.1, 167.3 (C=O Ac, CO₂Me), 131.9 (CH_{arom}), 131.5 (C_q SPh) 129.0, 128.1 (CH_{arom}), 83.8 (C-1), 71.3 (C-5), 68.4 (C-4), 60.7 (C-2), 60.1 (C-3), 52.6 (CH₃ CO₂Me), 20.4 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 83.8 (*J*_{C1,H1} = 168 Hz, C-1); HRMS [*M* + Na]⁺ calcd for C₁₅H₁₆N₆O₅Na 415.07951, found 415.07942.

Methyl (Phenyl 4-O-acetyl-2,3-diazido-2,3-dideoxy-1-thio- β -D-mannopyranosyl uronate) (8 β). Compound **16 β** (0.26 g, 0.74 mmol) was treated with Ac₂O/pyridine (6 mL, 1/3, v/v) until TLC analysis indicated complete consumption of the starting material. The mixture was diluted with EtOAc, washed with H₂O and saturated aqueous NaCl, dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 50% EtOAc in PE) yielded the title compound as a yellowish solid (0.29 g, 0.74 mmol, quant.): TLC *R_f* 0.31 (PE/EtOAc, 3/1, v/v); [α]_D²⁰ +19.8 (c 1, DCM); IR (neat, cm⁻¹) 1049, 1219, 1751, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.44–7.48 (m, 2H, CH_{arom}), 7.26–7.32 (m, 3H, CH_{arom}), 5.33 (t, 1H, *J* = 10.0 Hz, H-4), 5.00 (d, 1H, *J* = 1.3 Hz, H-1), 4.26 (dd, 1H, *J* = 1.1, 3.6 Hz, H-2), 4.05 (dd, 1H, *J* = 3.4, 10.3 Hz, H-3), 4.03 (d, 1H, *J* = 9.9 Hz, H-5), 3.69 (s, 3H, CH₃ CO₂Me), 2.06 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 169.2, 166.7 (C=O Ac, CO₂Me), 132.8 (C_q SPh), 131.4, 129.0, 128.0 (CH_{arom}), 86.6 (C-1), 76.3 (C-5), 67.6 (C-4), 64.0 (C-2), 63.4 (C-3), 52.6 (CH₃ CO₂Me), 20.2 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 86.6 (*J*_{C1,H1} = 156 Hz, C-1); HRMS [*M* + NH₄]⁺ calcd for C₁₅H₂₀N₇O₅S 410.12411, found 410.12400.

Methyl 4,6-O-Benzylidene-2,3-di-O-methanesulfonyl- α -D-glucofuranoside (10). Compound **9¹⁴** (17.4 g, 61.7 mmol) was dissolved in pyridine (123 mL), and methanesulfonyl chloride (14.4 mL, 186 mmol) was dropwise added. The mixture was stirred overnight and subsequently diluted with EtOAc and H₂O. The layers were separated, and the organic fraction was washed with saturated aqueous NaCl (2 \times), dried over Na₂SO₄, and concentrated in vacuo. Crude compound **10** was used in the next reaction step without further purification. A fraction was crystallized for analytical purposes. Spectroscopic data were in accord with those previously reported:³² TLC *R_f* 0.74 (DCM/acetone, 10/1, v/v); ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.41–7.48 (m, 2H, CH_{arom}), 7.35–7.40 (m, 3H, CH_{arom}), 5.56 (s, 1H, CH Ph), 5.09 (t, 1H, *J* = 9.6 Hz, H-3), 5.03 (d, 1H, *J* = 3.7 Hz, H-1), 4.63 (dd, 1H, *J* = 3.7, 9.6 Hz, H-2), 4.34 (dd, 1H, *J* = 4.8, 10.4 Hz, H-6), 3.94 (td, 1H, *J* = 4.8, 9.8, 9.9 Hz, H-5), 3.79 (t, 1H, *J* = 10.4 Hz, H-6), 3.74 (t, 1H, *J* = 9.5 Hz, H-4), 3.49 (s, 3H, OMe), 3.17 (s, 3H, CH₃ Ms), 2.97 (s, 3H, CH₃ Ms); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 136.2 (C_q Ph), 129.5, 128.4, 126.0 (CH_{arom}), 101.9 (CH Ph), 98.78 (C-1), 78.9 (C-4), 77.1 (C-3), 75.8 (C-2), 68.6 (C-6), 62.2 (C-5), 56.0 (OMe), 38.9, 38.7 (CH₃ Ms); HRMS [*M* + Na]⁺ calcd for C₁₆H₂₂O₁₀S₂Na 461.05466, found 461.05430.

Methyl 2,3-Anhydro-4,6-O-benzylidene- α -D-allopyranoside (11). Crude compound **10** (~62 mmol) was dissolved in THF/MeOH (500 mL, 2/3, v/v) followed by the addition of KOH (10.5 g, 187 mmol). The mixture was refluxed at 70 °C overnight. Then H₂O was added, the mixture diluted with EtOAc, and the organic fraction was separated and washed with H₂O (3 \times), dried over Na₂SO₄, and concentrated in vacuo. Crystallization (EtOAc/PE) yielded the title compound as a white fluffy solid (10.2 g, 39.5 mmol, 62% over two steps). Spectroscopic data

were in accord with those previously reported:³³ TLC *R_f* 0.56 (PE/EtOAc, 2/3, v/v); ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.47–7.52 (m, 2H, CH_{arom}), 7.35–7.40 (m, 3H, CH_{arom}), 5.57 (s, 1H, CH Ph), 4.89 (d, 1H, *J* = 2.8 Hz, H-1), 4.24 (dd, 1H, *J* = 5.0, 10.2 Hz, H-6), 4.05–4.12 (m, 1H, H-5), 3.95 (dd, 1H, *J* = 1.0, 9.1 Hz, H-4), 3.68 (t, 1H, *J* = 10.3 Hz, H-6), 3.52 (d, 1H, *J* = 4.3 Hz, H-3), 3.49 (dd, 1H, *J* = 2.8, 4.3 Hz, H-2), 3.47 (s, 3H, OMe); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 137.1 (C_q Ph), 129.2, 128.3, 126.3 (CH_{arom}), 102.7 (CH Ph), 95.3 (C-1), 77.9 (C-4), 68.9 (C-6), 60.0 (C-5), 55.8 (OMe), 53.1 (C-2), 50.7 (C-3); HRMS [*M* + H]⁺ calcd for C₁₄H₁₇O₅ 265.10705, found 265.10718.

Methyl 2-Azido-4,6-O-benzylidene-2-deoxy- α -D-altropyranoside (12). Compound **11** (13.6 g, 52 mmol) was dissolved in DMSO (260 mL), followed by the addition of NaN₃ (10.1 g, 155 mmol) and NH₄Cl (24.9 g, 466 mmol). The mixture was heated overnight at 80 °C and subsequently diluted with EtOAc, washed with saturated aqueous NaCl (3 \times), dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 50% EtOAc in PE) yielded the title compound as a colorless oil (14.8 g, 48.4 mmol, 93%): TLC *R_f* 0.51 (PE/EtOAc, 2/3, v/v); [α]_D²⁰ +68.9 (c 1, DCM); IR (neat, cm⁻¹) 1042, 1242, 1736, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.45–7.51 (m, 2H, CH_{arom}), 7.29–7.38 (m, 3H, CH_{arom}), 5.57 (s, 1H, CH Ph), 4.63 (s, 1H, H-1), 4.28 (dd, 1H, *J* = 5.2, 10.2 Hz, H-6), 4.16 (td, 1H, *J* = 5.2, 10.0, 10.0 Hz, H-5), 4.03 (s, 1H, H-3), 3.76–3.81 (m, 2H, H-2, H-4), 3.75 (t, 1H, *J* = 10.3 Hz, H-6), 3.37 (s, 3H, OMe), 3.14 (bs, 1H, 3-OH); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 136.9 (C_q Ph), 128.9, 128.0, 126.0 (CH_{arom}), 101.9 (CH Ph), 99.1 (C-1), 75.7 (C-4), 68.7 (C-6), 67.1 (C-3), 61.6 (C-2), 57.8 (C-5), 55.5 (OMe); ¹³C-GATED (CDCl₃, 100 MHz) δ 99.1 (*J*_{C1,H1} = 171 Hz, C-1); HRMS [*M* + H]⁺ calcd for C₁₄H₁₈N₃O₅ 308.12410, found 308.12414.

Methyl 2,3-Diazido-4,6-O-benzylidene-2,3-dideoxy- α -D-mannopyranoside (13). A solution of compound **12** (14.85 g, 48.4 mmol) in DCE (340 mL) was treated with pyridine (91 mL, 1.13 mol) and Tf₂O (18.9 mL, 112.5 mmol). The reaction was stirred for 30 min, followed by the addition of H₂O to quench. The mixture was diluted with DCM, washed with H₂O (3 \times), dried over Na₂SO₄, and concentrated in the presence of toluene (2 \times). The crude triflate (~48 mmol) was dissolved in DMF (110 mL). NaN₃ (18.7 g, 288 mmol) and NH₄Cl (9.0 g, 168 mmol) were added, and the mixture was heated overnight at 80 °C. EtOAc and H₂O were added, and the layers were separated. The organic phase was washed with H₂O (2 \times), dried over Na₂SO₄, and concentrated in vacuo. Purification using column chromatography (silica gel, 50% EtOAc in PE) furnished the title compound as a white amorphous solid (12.1 g, 36.3 mmol, 75%): TLC *R_f* 0.75 (PE/EtOAc, 4/1, v/v); [α]_D²⁰ +94.0 (c 1, DCM); IR (neat, cm⁻¹) 1041, 1735, 2106, 2931; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.47–7.52 (m, 2H, CH_{arom}), 7.35–7.41 (m, 3H, CH_{arom}), 5.65 (s, 1H, CH Ph), 4.71 (d, 1H, *J* = 1.4 Hz, H-1), 4.29 (dd, 1H, *J* = 10.6, 16.2 Hz, H-6), 4.14 (dd, 1H, *J* = 3.6, 10.2 Hz, H-3), 4.05 (dt, 1H, *J* = 1.6, 10.2 Hz, H-4), 3.90 (dd, 1H, *J* = 1.4, 3.6 Hz, H-2), 3.82–3.85 (m, 2H, H-5, H-6), 3.40 (s, 3H, OMe); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 136.8 (C_q), 129.0, 128.3, 125.8 (CH_{arom}), 101.6 (CH Ph), 99.3 (C-1), 77.5 (C-4), 68.7 (C-6), 63.8 (C-5), 62.7 (C-2), 59.2 (C-3), 55.2 (OMe); HRMS [*M* + H]⁺ calcd for C₁₄H₁₇N₆O₄ 333.13058, found 333.13036.

Acetyl 4,6-Di-O-acetyl-2,3-diazido-2,3-dideoxy- α / β -D-mannopyranoside (14). Compound **13** (20.7 mmol) was dissolved in Ac₂O (35 mL) and treated with H₂SO₄ (0.3 mL) at 0 °C for 2 h. The mixture was diluted with EtOAc and quenched with saturated aqueous NaHCO₃. The organic fraction was washed with H₂O and saturated aqueous NaCl (2 \times). Purification using flash column chromatography (silica gel, 50% EtOAc in PE) furnished the title compound as a brownish oil (7.3 g, 20.5 mmol, 98%, α/β = 5:1): TLC *R_f* 0.45 (PE/EtOAc, 1/1, v/v); IR (neat, cm⁻¹) 1211, 1735, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 6.12 (d, 1H, *J* = 1.6 Hz, H-1 α), 5.85 (d, 0.2H, *J* = 0.9 Hz, H-1 β), 5.33 (t, 1H, *J* = 10.1 Hz, H-4 α), 5.21 (t, 0.2H, *J* = 9.9 Hz,

H-4 β), 4.22–4.27 (m, 0.2H, H-6 β), 4.20 (dd, 1H, $J = 4.6, 12.5$ Hz, H-6 α), 4.11 (d, 0.2H, $J = 2.3$ Hz, H-2 β), 4.07–4.14 (m, 1.2H, H-6 α , H-6 β), 4.05–4.07 (m, 1H, H-3 α), 3.95–4.00 (m, 2H, H-2 α , H-5 α), 3.73–3.80 (m, 0.4H, H-3 β , H-5 β), 2.20 (s, 0.6H, CH₃ Ac- β), 2.17 (s, 3H, CH₃ Ac- α), 2.15 (s, 3H, CH₃ Ac- α), 2.13 (s, 0.6H, CH₃ Ac- β), 2.09 (s, 3H, CH₃ Ac- α); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.3, 169.1, 169.1, 168.1, 167.9 (C=O Ac), 91.5 (C-1 β), 90.6 (C-1 α), 73.5 (C-5 β), 70.4 (C-5 α), 66.2 (C-4 α), 65.7 (C-4 β), 61.7 (C-2 β), 61.5 (C-6 α , C-6 β), 61.3 (C-3 β), 60.9 (C-2 α), 59.8 (C-3 α), 20.5, 20.4, 20.3, 20.3, 20.3 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 91.5 ($J_{C1,H1} = 162$ Hz, C-1 β), 90.6 ($J_{C1,H1} = 175$ Hz, C-1 α); HRMS [M + Na]⁺ calcd for C₁₂H₁₆N₆O₇Na 379.09727, found 379.09719.

Phenyl 2,3-Diazido-2,3-dideoxy-1-thio- α -D-mannopyranoside (15 α). Compound **6 α** (0.78 g, 2.0 mmol) was suspended in MeOH (10 mL) and treated with NaOMe (39 mg, 0.72 mmol) for 2 h. The mixture was neutralized by the addition of Amberlite-H⁺, filtered, and reduced in volume. The residue was taken up in EtOAc, washed with saturated aqueous NaCl (2 \times), dried over Na₂SO₄, and concentrated in vacuo. The product was obtained as a yellow oil (0.65 g, 2.0 mmol, quant.): TLC R_f 0.16 (PE/EtOAc, 2/1, v/v); [α]_D²⁰ +72.1 (c 1, DCM); IR (neat, cm⁻¹) 727, 905, 1065, 2102, 3337; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.42–7.46 (m, 2H, CH_{arom}), 7.29–7.35 (m, 3H, CH_{arom}), 5.46 (s, 1H, H-1), 4.36 (bs, 1H, 4-OH), 4.05–4.15 (m, 3H, H-2, H-4, H-5), 3.86–3.92 (m, 2H, H-3, H-6), 3.79 (dd, 1H, $J = 1.3, 12.3$ Hz, H-6), 3.04 (bs, 1H, 6-OH); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 132.4 (C_q SPh), 132.1, 129.2, 128.2 (CH_{arom}), 86.1 (C-1), 73.3 (C-4), 66.4 (C-5), 63.8 (C-2), 62.9 (C-3), 61.3 (C-6); ¹³C-GATED (CDCl₃, 100 MHz) δ 86.1 ($J_{C1,H1} = 168$ Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₁₂H₁₈N₇O₃S 340.11863, found 340.11869.

Phenyl 2,3-Diazido-2,3-dideoxy-1-thio- β -D-mannopyranoside (15 β). Compound **6 β** (3.22 g, 7.93 mmol) was suspended in MeOH (40 mL) and treated with NaOMe (43 mg, 0.79 mmol) for 1.5 h, after which time the mixture was neutralized by the addition of Amberlite-H⁺, filtered, and concentrated in vacuo. The title compound was obtained as an off-white fluffy solid (2.50 g, 7.76 mmol, 98%): TLC R_f 0.39 (PE/EtOAc, 1/1, v/v); [α]_D²⁰ +22.7 (c 1, MeOH); IR (neat, cm⁻¹) 1074, 2104, 3211, 3366; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.45–7.50 (m, 2H, CH_{arom}), 7.30–7.37 (m, 3H, CH_{arom}), 4.87 (s, 1H, H-1), 4.10 (d, 1H, $J = 3.3$ Hz, H-2), 4.06 (t, 1H, $J = 9.7$ Hz, H-4), 3.90 (dd, 1H, $J = 3.2, 12.3$ Hz, H-6), 3.84 (dd, 1H, $J = 4.0, 12.2$ Hz, H-6), 3.69 (dd, 1H, $J = 3.5, 9.9$ Hz, H-3), 3.30–3.36 (m, 1H, H-5), 1.39 (bs, 2H, 4-OH, 6-OH); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 133.4 (C_q SPh), 131.2, 129.1, 127.9 (CH_{arom}), 86.4 (C-1), 80.9 (C-5), 66.2 (C-3), 65.6 (C-4), 64.7 (C-2), 61.3 (C-6); ¹³C-GATED (CDCl₃, 100 MHz) δ 86.4 ($J_{C1,H1} = 155$ Hz, C-1); HRMS [M + Na]⁺ calcd for C₁₂H₁₄N₆O₃SNa 345.07403, found 345.07380.

Methyl (Phenyl 2,3-diazido-2,3-dideoxy-1-thio- α -D-mannopyranosyl uronate) (16 α). Diol **15 α** (0.37 g, 1.15 mmol) was dissolved in DCM (4 mL), and H₂O (2 mL) was added. The mixture was cooled to 0 °C, followed by the addition of TEMPO (36 mg, 0.23 mmol) and BAIB (0.93 g, 2.88 mmol). The resulting emulsion was stirred at rt for 1.5 h. The reaction was quenched by the addition of saturated aqueous Na₂S₂O₃, and the organic layer was washed with saturated aqueous NaCl (2 \times), dried over MgSO₄, and concentrated in vacuo. The crude product was dissolved in dry DMF (10 mL) and treated with MeI (0.2 mL, 3.45 mmol) and K₂CO₃ (0.48 g, 3.45 mmol) at rt overnight. The mixture was diluted with EtOAc and H₂O, and the organic layer was washed with saturated aqueous NaCl (2 \times), dried over MgSO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 25% EtOAc in PE) gave the title compound as a yellowish oil (0.29 g, 0.82 mmol, 71%): TLC R_f 0.70 (PE/EtOAc, 1/1, v/v); [α]_D²⁰ +86.4 (c 1, DCM); IR (neat, cm⁻¹) 727, 1078, 1250, 1439, 1734, 2102, 3487; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.47–7.52 (m, 2H, CH_{arom}), 7.28–7.36 (m, 3H, CH_{arom}), 5.50

(d, 1H, $J = 1.3$ Hz, H-1), 4.71 (d, 1H, $J = 9.1$ Hz, H-5), 4.26 (t, 1H, $J = 9.0$ Hz, H-4), 4.09 (s, 1H, H-2), 3.91 (dd, 1H, $J = 3.4, 9.4$ Hz, H-3), 3.81 (s, 3H, CH₃ CO₂Me), 3.68 (d, 1H, $J = 1.9$ Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.0 (C=O CO₂Me), 132.1 (C_q SPh), 132.0, 129.2, 128.3 (CH_{arom}), 86.2 (C-1), 71.6 (C-5), 68.2 (C-4), 62.7 (C-2), 61.7 (C-3), 52.9 (CH₃ CO₂Me); ¹³C-GATED (CDCl₃, 100 MHz) δ 86.2 ($J_{C1,H1} = 169$ Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₁₃H₁₈N₇O₄S 368.11355, found 368.11356.

Methyl (Phenyl 2,3-diazido-2,3-dideoxy-1-thio- β -D-mannopyranosyl uronate) (16 β). Diol **15 β** (0.51 g, 1.58 mmol) was dissolved in EtOAc (6 mL), and H₂O (3 mL) was added. The mixture was cooled to 0 °C, followed by the addition of TEMPO (50 mg, 0.32 mmol) and BAIB (1.27 g, 3.95 mmol). The resulting emulsion was stirred at rt for 1 h. The reaction was quenched by the addition of saturated aqueous Na₂S₂O₃, and the organic layer was washed with saturated aqueous NaCl (2 \times), dried over MgSO₄, and concentrated in vacuo. The crude product was dissolved in dry DMF (9 mL) and treated with MeI (0.3 mL, 4.74 mmol) and K₂CO₃ (0.66 g, 4.74 mmol) at rt overnight. The mixture was diluted with EtOAc and H₂O, and the organic layer was washed with saturated aqueous NaCl (2 \times), dried over MgSO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 33% EtOAc in PE) gave the title compound as an off-white solid (0.50 g, 1.43 mmol, 91%): TLC R_f 0.29 (PE/EtOAc, 2/1, v/v); [α]_D²⁰ -13.8 (c 1, DCM); IR (neat, cm⁻¹) 1034, 1265, 1288, 1736, 2106, 3741; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.49–7.55 (m, 2H, CH_{arom}), 7.28–7.36 (m, 3H, CH_{arom}), 4.84 (s, 1H, H-1), 4.22 (t, 1H, $J = 9.6$ Hz, H-4), 4.08 (d, 1H, $J = 2.9$ Hz, H-2), 3.81–3.86 (m, 4H, H-5, CH₃ CO₂Me), 3.72 (dd, 1H, $J = 3.5, 9.7$ Hz, H-3), 3.60 (bs, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 169.2 (C=O CO₂Me), 133.1 (C_q SPh), 131.8, 129.1, 128.2 (CH_{arom}), 87.2 (C-1), 77.8 (C-5), 67.7 (C-4), 65.2 (C-3), 63.8 (C-2), 53.0 (CH₃ CO₂Me); ¹³C-GATED (CDCl₃, 100 MHz) δ 87.2 ($J_{C1,H1} = 155$ Hz, C-1); HRMS [M + Na]⁺ calcd for C₁₃H₁₄N₆O₄SNa 373.06894, found 373.06854.

Methyl 6-O-(4,6-Di-O-acetyl-2,3-diazido-2,3-dideoxy- α -D-mannopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (23). Donor **6 β** and acceptor **20** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **23** (75%, $\alpha/\beta = 1:1$). TLC R_f α 0.44, β 0.15 (toluene/EtOAc, 2/3, v/v); IR (neat, cm⁻¹) 1042, 1227, 1744, 2098, 2924. Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.24–7.40 (m, 15H, CH_{arom}), 5.22 (t, 1H, $J = 10.0$ Hz, H-4'), 5.02 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.98 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.89 (d, 1H, $J = 1.0$ Hz, H-1'), 4.80 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.80 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.69 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.60 (d, 1H, $J = 3.0$ Hz, H-1), 4.59 (d, 1H, $J = 12.0$ Hz, CHH Bn), 3.98–4.06 (m, 2H, H-3, H-6'), 3.96 (dd, 1H, $J = 2.4, 12.4$ Hz, H-6'), 3.82–3.90 (m, 3H, H-2', H-3', H-6), 3.73–3.78 (m, 2H, H-5, H-5'), 3.65 (dd, 1H, $J = 1.6, 11.2$ Hz, H-6), 3.52 (dd, 1H, $J = 3.6, 9.6$ Hz, H-2), 3.46 (t, 1H, $J = 9.2$ Hz, H-4), 3.38 (s, 3H, OMe), 2.09 (s, 3H, CH₃ Ac), 2.02 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.6, 169.3 (C=O Ac), 138.4, 138.0, 137.9 (C_q Bn), 128.5, 128.4, 128.0, 127.4 (CH_{arom}), 97.9 (C-1), 97.7 (C-1'), 82.0 (C-3), 79.9 (C-2), 77.2 (C-4), 75.8, 74.7, 73.3 (CH₂ Bn), 69.5, 68.7 (C-5, C-5'), 66.8 (C-4'), 66.5 (C-6), 62.1 (C-2'), 61.9 (C-6'), 60.3 (C-3'), 55.3 (OMe), 20.6, 20.6 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 97.9 ($J_{C1,H1} = 163$ Hz, C-1), 97.7 ($J_{C1,H1} = 173$ Hz, C-1'). Spectroscopic data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.25–7.39 (m, 15H, CH_{arom}), 5.12 (t, 1H, $J = 9.9$ Hz, H-4'), 5.00 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.88 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.81 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.79 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.64 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.59 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.56 (d, 1H, $J = 3.5$ Hz, H-1), 4.33 (s, 1H, H-1'), 4.20 (dd, 1H, $J = 5.2, 12.3$ Hz, H-6'), 4.06–4.14 (m, 2H, H-6, H-6'), 4.02 (t, 1H, $J = 9.2$ Hz, H-3), 3.83 (ddd, 1H, $J = 1.4, 5.7, 9.7$ Hz, H-5), 3.71 (d, 1H, $J = 3.3$ Hz,

H-2'), 3.53 (dd, 1H, $J = 5.9, 10.4$ Hz, H-6), 3.49 (dd, 1H, $J = 3.5, 9.7$ Hz, H-2), 3.43–3.47 (m, 1H, H-5'), 3.35–3.41 (m, 5H, H-3', H-4, OMe), 2.10 (s, 3H, CH₃ Ac), 2.03 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.7, 169.2 (C=O Ac), 138.6, 138.4, 138.0 (C_q Bn), 128.4, 128.1, 128.0, 127.9, 127.8, 127.6 (CH_{arom}), 100.3 (C-1'), 97.9 (C-1), 82.0 (C-3), 79.9 (C-2), 77.3 (C-4), 75.7, 74.5, 73.4 (CH₂ Bn), 73.0 (C-5'), 69.5 (C-5), 68.8 (C-6), 66.7 (C-4'), 62.5 (C-2'), 62.3 (C-6'), 61.4 (C-3'), 55.2 (OMe), 20.7, 20.6 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.3 ($J_{C1,H1} = 156$ Hz, C-1'), 97.9 ($J_{C1,H1} = 162$ Hz, C-1); HRMS [M + Na]⁺ calcd for C₃₈H₄₄N₆O₁₁Na 783.29603, found 783.29585.

Methyl 4-O-(4,6-Di-O-acetyl-2,3-diazido-2,3-dideoxy- α / β -D-mannopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (24). Donor **6 β** and acceptor **21** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **24** (45%, $\alpha/\beta = 2:1$). TLC R_f 0.24, 0.38 (PE/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 1042, 1234, 1744, 2106, 2924. Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.25–7.41 (m, 15H, CH_{arom}), 5.19 (t, 1H, $J = 10.0$ Hz, H-4'), 5.15 (d, 1H, $J = 1.7$ Hz, H-1'), 5.11 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.74 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58–4.65 (m, 4H, CH₂ Bn, H-1), 4.51 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.03 (dd, 1H, $J = 4.6, 12.3$ Hz, H-6'), 3.92 (t, 1H, $J = 9.1$ Hz, H-3), 3.77–3.87 (m, 3H, H-3', H-5', H-6'), 3.73–3.77 (m, 1H, H-5), 3.71 (t, 1H, $J = 8.7$ Hz, H-4), 3.65–3.68 (m, 2H, H-6), 3.55 (dd, 1H, $J = 3.5, 9.6$ Hz, H-2), 3.50 (dd, 1H, $J = 1.9, 3.3$ Hz, H-2'), 3.41 (s, 3H, OMe), 2.10 (s, 3H, CH₃ Ac), 2.03 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.6, 169.3 (C=O Ac), 138.0, 137.8, 137.6 (C_q Bn), 128.7, 128.5, 128.4, 128.1, 128.0, 127.7, 127.5 (CH_{arom}), 99.5 (C-1'), 97.7 (C-1), 80.9 (C-3), 80.3 (C-2), 77.8 (C-4), 75.5, 73.5, 73.2 (CH₂ Bn), 69.5, 69.4 (C-5, C-5'), 69.0 (C-6), 67.0 (C-4'), 62.1 (C-6'), 62.0 (C-2'), 60.3 (C-3'), 55.4 (OMe), 20.7, 20.6 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 99.5 ($J_{C1,H1} = 171$ Hz, C-1'), 97.7 ($J_{C1,H1} = 163$ Hz, C-1). Spectroscopic data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.26–7.42 (m, 15H, CH_{arom}), 5.06 (t, 1H, $J = 10.0$ Hz, H-4'), 4.99 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.86 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.77 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.74 (d, 1H, $J = 13.2$ Hz, CHH Bn), 4.58–4.63 (m, 2H, CHH Bn, H-1), 4.54 (d, 1H, $J = 1.1$ Hz, H-1'), 4.39 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.02 (dd, 1H, $J = 4.3, 12.4$ Hz, H-6'), 3.91 (t, 1H, $J = 8.8$ Hz, H-3), 3.89 (t, 1H, $J = 8.8$ Hz, H-4), 3.80 (dd, 1H, $J = 2.6, 12.4$ Hz, H-6'), 3.72–3.77 (m, 2H, H-5, H-6), 3.61–3.65 (m, 1H, H-6), 3.51 (dd, 1H, $J = 3.6, 9.1$ Hz, H-2), 3.38 (s, 3H, OMe), 3.37 (dd, 1H, $J = 0.7, 3.4$ Hz, H-2'), 3.16 (ddd, 1H, $J = 2.6, 4.2, 9.7$ Hz, H-5'), 2.94 (dd, 1H, $J = 3.5, 10.2$ Hz, H-3'), 2.08 (s, 3H, CH₃ Ac), 1.97 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.6, 169.1 (C=O Ac), 139.2, 128.0, 137.5 (C_q Bn), 128.7, 128.6, 128.4, 128.2, 128.1, 127.9, 127.3 (CH_{arom}), 100.1 (C-1'), 98.2 (C-1), 80.0 (C-3), 79.2 (C-2), 77.7 (C-4), 74.9, 73.7, 73.4 (CH₂ Bn), 72.9 (C-5'), 69.3 (C-5), 68.1 (C-6), 66.2 (C-4'), 62.6 (C-2'), 61.8 (C-6'), 61.5 (C-3'), 55.4 (OMe), 20.7, 20.6 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.1 ($J_{C1,H1} = 155$ Hz, C-1'), 98.2 ($J_{C1,H1} = 164$ Hz, C-1); HRMS [M + Na]⁺ calcd for C₃₈H₄₄N₆O₁₁Na 783.29603, found 783.29586.

p-Methoxyphenyl 3-O-(4,6-di-O-acetyl-2,3-diazido-2,3-dideoxy- α / β -D-mannopyranosyl)-2-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (25). Donor **6 β** and acceptor **22** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **25** (66%, $\alpha/\beta = 2.5:1$). TLC R_f α 0.75, β 0.50 (toluene/EtOAc, 1/1, v/v); IR (neat, cm⁻¹) 1049, 1219, 1504, 1744, 2106, 2924, 3742. Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.52–7.56 (m, 2H, CH_{arom}), 7.39–7.43 (m, 3H, CH_{arom}), 7.30–7.36 (m, 5H, CH_{arom}), 7.06 (d, 2H, $J = 9.1$ Hz, CH_{arom}), 6.83 (d, 1H, $J = 9.1$ Hz, CH_{arom}), 5.57 (s, 1H, CH Ph), 5.24 (t, 1H, $J = 10.1$ Hz, H-4'), 5.08 (d, 1H, $J = 11.0$ Hz, CHH Bn), 5.02 (d, 1H, $J = 1.1$ Hz, H-1'), 4.90 (d, 1H, $J = 7.7$ Hz, H-1), 4.73 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.37 (dd, 1H, $J = 1.2, 12.4$ Hz, H-6),

4.30 (d, 1H, $J = 3.5$ Hz, H-4), 4.02–4.11 (m, 3H, H-2, H-5', H-6), 3.94 (dd, 1H, $J = 2.4, 12.6$ Hz, H-6'), 3.82–3.92 (m, 4H, H-2', H-3, H-3', H-6'), 3.77 (s, 3H, OMe), 3.47 (s, 1H, H-5), 2.06 (s, 3H, CH₃ Ac), 2.03 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.6, 169.3 (C=O Ac), 155.5, 151.3, 138.0, 137.4 (C_q Ph, Bn), 129.2, 128.4, 128.2, 128.1, 127.9, 126.3, 118.8, 114.5 (CH_{arom}), 103.4 (C-1), 101.1 (CH Ph), 93.2 (C-1'), 76.2 (C-2), 75.1 (CH₂ Bn), 74.0 (C-3), 71.1 (C-4), 69.1 (C-6), 68.6 (C-5'), 66.6 (C-4'), 66.2 (C-5), 62.0 (C-2'), 61.5 (C-6'), 60.5 (C-3'); 55.6 (OMe), 20.7, 20.6 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 103.4 ($J_{C1,H1} = 159$ Hz, C-1), 93.2 ($J_{C1,H1} = 171$ Hz, C-1'); HRMS [M + Na]⁺ calcd for C₃₇H₄₀N₆O₁₂Na 783.25964, found 783.25923.

Methyl 6-O-(2,3-Diazido-4,6-O-benzylidene-2,3-dideoxy- α / β -D-mannopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (26). Donor **7** and acceptor **20** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **26** (79%, $\alpha/\beta = 3:1$). TLC R_f 0.65 (PE/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 698, 743, 1030, 1067, 1072, 2106. Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.43–7.49 (m, 2H, CH_{arom}), 7.25–7.40 (m, 18H, CH_{arom}), 5.62 (s, 1H, CH Ph), 5.01 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.95 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.77–4.84 (m, 3H, CH₂ Bn, H-1'), 4.68 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.60 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.59 (d, 1H, $J = 3.5$ Hz, H-1), 4.17 (dd, 1H, $J = 3.2, 8.8$ Hz, H-6'), 3.98–4.05 (m, 3H, H-3, H-3', H-4'), 3.85 (d, 1H, $J = 2.8$ Hz, H-2'), 3.71–3.83 (m, 4H, H-5, H-5', H-6, H-6'), 3.63 (dd, 1H, $J = 1.5, 11.3$ Hz, H-6), 3.52 (dd, 1H, $J = 3.5, 9.6$ Hz, H-2), 3.46 (t, 1H, $J = 9.4$ Hz, H-4), 3.37 (s, 3H, OMe); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 138.5, 137.9, 137.8, 136.8 (C_q), 129.0, 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 127.7, 125.8 (CH_{arom}), 101.6 (CH Ph), 98.6 (C-1'), 97.9 (C-1), 82.0 (C-3), 79.9 (C-2), 77.5 (C-4'), 77.1 (C-4), 75.7, 74.9, 73.3 (CH₂ Bn), 69.6 (C-5), 68.5 (C-6'), 66.5 (C-6), 64.1 (C-5'), 62.6 (C-2'), 59.1 (C-3'), 55.3 (OMe); ¹³C-GATED (CDCl₃, 100 MHz) δ 98.6 ($J_{C1,H1} = 174$ Hz, C-1'), 97.9 ($J_{C1,H1} = 171$ Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₄₁H₄₈N₇O₉ 782.35080, found 782.35125.

Methyl 4-O-(2,3-Diazido-4,6-O-benzylidene-2,3-dideoxy- α / β -D-mannopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (27). Donor **7** and acceptor **21** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **27** (66%, $\alpha/\beta = 5:1$). TLC R_f 0.40 (PE/EtOAc, 3/1, v/v); IR (neat, cm⁻¹) 698, 737, 1028, 1047, 1096, 2106, 2928. Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.44–7.49 (m, 2H, CH_{arom}), 7.23–7.41 (m, 18H, CH_{arom}), 5.59 (s, 1H, CH Ph), 5.16 (s, 1H, H-1'), 5.11 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.74 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.60–4.68 (m, 3H, CHH Bn, CHH Bn, H-1), 4.57 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.52 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.05 (dd, 1H, $J = 4.7, 10.3$ Hz, H-6'), 3.98–4.01 (m, 2H, H-3', H-4'), 3.94 (t, 1H, $J = 9.1$ Hz, H-3), 3.80–3.86 (m, 1H, H-5'), 3.79 (t, 1H, $J = 9.2$ Hz, H-4), 3.63–3.74 (m, 4H, H-5, H-6, H-6, H-6'), 3.53–3.58 (m, 2H, H-2, H-2'), 3.39 (s, 3H, OMe); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 138.1, 137.7, 136.9 (C_q), 129.0, 128.9, 128.8, 128.7, 128.5, 128.3, 128.2, 128.1, 128.0, 127.6, 127.0, 125.8 (CH_{arom}), 101.6 (CH Ph), 100.0 (C-1'), 97.7 (C-1), 81.2 (C-3), 80.3 (C-2), 77.3 (C-4'), 76.7 (C-4), 75.5, 73.6, 73.2 (CH₂ Bn), 69.4 (C-5), 68.8, 68.5 (C-6, C-6'), 64.8 (C-5'), 62.6 (C-2'), 59.2 (C-3'), 55.4 (OMe); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.0 ($J_{C1,H1} = 176$ Hz, C-1'), 97.7 ($J_{C1,H1} = 167$ Hz); HRMS [M + NH₄]⁺ calcd for C₄₁H₄₈N₇O₉ 782.35080, found 782.35123.

p-Methoxyphenyl 3-O-(2,3-Diazido-4,6-O-benzylidene-2,3-dideoxy- α / β -D-mannopyranosyl)-2-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (28). Donor **7** and acceptor **22** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **28** (81%, $\alpha/\beta = 1:1$): TLC R_f 0.44 (PE/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 696, 729, 1057, 1078, 1219, 1506, 2104; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.51–7.60 (m, 4H, CH_{arom}), 7.32–7.48

(m, 26H, CH_{arom}), 7.06 (d, 4H, *J* = 9.0 Hz, CH_{arom}), 6.80–6.85 (m, 4H, CH_{arom}), 5.61 (s, 1H, CH Ph- α), 5.59 (s, 1H, CH Ph- β), 5.56 (s, 1H, CH Ph- α), 5.55 (s, 1H, CH Ph- β), 5.10 (d, 1H, *J* = 11.5 Hz, CHH Bn- β), 4.98 (s, 1H, H-1' α), 4.98 (d, 1H, *J* = 10.8 Hz, CHH Bn- α), 4.93 (s, 1H, H-1' β), 4.90 (d, 1H, *J* = 7.8 Hz, H-1), 4.90 (d, 1H, *J* = 7.7 Hz, H-1), 4.79 (d, 1H, *J* = 10.9 Hz, CHH Bn- α), 4.67 (d, 1H, *J* = 11.6 Hz, CHH Bn- β), 4.36 (dd, 2H, *J* = 3.4, 12.2 Hz, H-6 α , H-6 β), 4.26–4.32 (m, 3H, H-4 α , H-4 β , H-6' β), 4.00–4.22 (m, 8H, H-2 α , H-2 β , H-3' α , H-4' α , H-5' α , H-6 α , H-6 β , H-6' β), 3.81–3.90 (m, 5H, H-2' α , H-3 α , H-3 β , H-4' β , H-6' α), 3.73–3.78 (m, 7H, H-6' α , CH₃ OMe- α , CH₃ OMe- β), 3.51 (s, 1H, H-5), 3.46 (s, 1H, H-5), 3.30 (d, 1H, *J* = 3.5 Hz, H-2' β), 3.23–3.27 (m, 1H, H-5' β), 3.21 (dd, 1H, *J* = 3.6, 10.1 Hz, H-3' β); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 155.4, 155.4, 151.3, 138.5, 137.8, 137.6, 137.4, 137.0, 136.5 (C_q), 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.3, 128.1, 127.9, 126.3, 126.2, 126.0, 125.8, 125.3, 118.9, 118.7, 114.5, 114.4 (CH_{arom}), 103.4, 103.2 (C-1 α , C-1 β), 101.6, 101.5, 101.4 (C-1' β , CH Ph, CH Ph), 101.1, 100.5 (CH Ph), 93.8 (C-1' α), 79.1 (C-2), 77.5 (C-4' α), 77.2, 76.7 (C-3), 76.2 (C-2), 75.6 (C-4), 75.5, 75.5 (CH₂ Bn), 73.8 (C-4' β), 70.9 (C-4), 69.1, 68.8 (C-6), 68.4, 68.3 (C-6' α , C-6' β), 68.0 (C-5' β), 66.6, 66.1 (C-5 α , C-5 β), 63.9 (C-5' α), 62.5, 62.4 (C-2' α , C-2' β), 60.3 (C-3' β), 59.1 (C-3' α), 55.6 (OMe); ¹³C-HMBC (CDCl₃, 100 MHz) δ 103.4 (*J*_{C1,H1} = 161 Hz, C-1), 103.2 (*J*_{C1,H1} = 159 Hz, C-1), 101.4 (*J*_{C1,H1} = 164 Hz, C-1' β), 93.8 (*J*_{C1,H1} = 171 Hz, C-1' α); HRMS [M + NH₄]⁺ calcd for C₄₀H₄₄N₇O₁₀ 782.31442, found 782.31459.

Methyl 6-O-(Methyl 4-O-acetyl-2,3-diazido-2,3-dideoxy- α/β -D-mannopyranosyl uronate)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (29). Donor **8 β** and acceptor **20** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **29** (94%, α/β = 1:5.5). TLC *R_f* α 0.55, β 0.45 (toluene/EtOAc, 3/1, v/v); IR (neat, cm⁻¹) 1065, 1751, 2106, 2916. Spectroscopic data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.26–7.38 (m, 15H, CH_{arom}), 5.24 (t, 1H, *J* = 9.8 Hz, H-4'), 5.00 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.87 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.81 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.78 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.64 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.58 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.55 (d, 1H, *J* = 3.5 Hz, H-1), 4.34 (s, 1H, H-1'), 4.08–4.13 (m, 1H, H-6), 4.01 (t, 1H, *J* = 9.2 Hz, H-3), 3.77–3.84 (m, 1H, H-5), 3.79 (d, 1H, *J* = 9.6 Hz, H-5'), 3.73 (s, 3H, CH₃ CO₂Me), 3.71 (d, 1H, *J* = 3.5 Hz, H-2'), 3.46–3.53 (m, 2H, H-3', H-6), 3.45 (dd, 1H, *J* = 3.6, 10.2 Hz, H-2), 3.36 (t, 1H, *J* = 9.2 Hz, H-4), 3.35 (s, 3H, OMe), 2.08 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 169.1, 166.8 (C=O Ac, CO₂Me), 138.6, 138.3, 138.0 (C_q Bn), 128.4, 128.3, 128.1, 128.0, 127.9, 127.7, 127.6 (CH_{arom}), 100.2 (C-1'), 97.8 (C-1), 81.9 (C-3), 79.9 (C-2), 77.2 (C-4), 75.7, 74.5 (CH₂ Bn), 73.7 (C-5 or C-5'), 73.4 (CH₂ Bn), 69.4 (C-5 or C-5'), 68.9 (C-6), 67.4 (C-4'), 62.2 (C-2'), 60.9 (C-3'), 55.1 (OMe), 52.8 (CH₃ CO₂Me), 20.5 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.2 (*J*_{C1,H1} = 159 Hz, C-1'), 97.8 (*J*_{C1,H1} = 172 Hz, C-1); HRMS [M + Na]⁺ calcd for C₃₇H₄₂N₆O₁₁Na 769.28038, found 769.28029.

Methyl 4-O-(Methyl 4-O-acetyl-2,3-diazido-2,3-dideoxy- α/β -D-mannopyranosyl uronate)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (30). Donor **8 β** and acceptor **21** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **30** (49%, α/β = 1:3.5). TLC *R_f* 0.27, 0.38 (PE/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 1041, 1751, 2106, 2924. Spectroscopic data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.22–7.45 (m, 15H, CH_{arom}), 5.10 (t, 1H, *J* = 10.0 Hz, H-4'), 5.02 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.84 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.78 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.72 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.60 (d, 1H, *J* = 3.7 Hz, H-1), 4.57 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.53 (d, 1H, *J* = 0.9 Hz, H-1'), 4.36 (d, 1H, *J* = 12.1 Hz, CHH Bn), 3.93 (t, 1H, *J* = 9.0 Hz, H-3), 3.87 (t, 1H, *J* = 9.2 Hz, H-4), 3.72–3.77 (m, 2H, H-5, H-6), 3.62 (dd, 1H, *J* = 2.2, 10.8 Hz, H-6), 3.49–3.53 (m, 5H, H-2, H-5', CH₃ CO₂Me), 3.38 (s, 3H, OMe), 3.27 (dd, 1H, *J* = 0.4, 3.3 Hz, H-2'), 2.98 (dd, 1H, *J* = 3.4, 10.2 Hz, H-3'), 2.07 (s, 3H, CH₃ Ac); ¹³C-APT NMR

(CDCl₃, 100 MHz, HSQC) δ 169.2, 166.6 (C=O Ac, CO₂Me), 139.3, 138.0, 137.6 (C_q Bn), 128.8, 128.7, 128.4, 128.1, 127.8, 127.3, 127.1 (CH_{arom}), 100.2 (C-1'), 98.2 (C-1), 80.0 (C-4), 79.3 (C-2), 78.4 (C-3), 75.0 (CH₂ Bn), 73.8 (C-5'), 73.7, 73.4 (CH₂ Bn), 68.9 (C-5), 68.0 (C-6), 67.4 (C-4'), 62.5 (C-2'), 60.9 (C-3'), 55.4 (OMe), 52.6 (CH₃ CO₂Me), 20.5 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.2 (*J*_{C1,H1} = 159 Hz, C-1'), 98.2 (*J*_{C1,H1} = 168 Hz, C-1); Spectroscopic data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.28–7.40 (m, 15H, CH_{arom}), 5.40 (d, 1H, *J* = 3.3 Hz, H-1'), 5.29 (t, 1H, *J* = 8.2 Hz, H-4'), 5.11 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.74 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.69 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.61–4.65 (m, 2H, CHH Bn, H-1), 4.55 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.48 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.24 (d, 1H, *J* = 7.9 Hz, H-5'), 3.97 (t, 1H, *J* = 9.1 Hz, H-3), 3.93 (dd, 1H, *J* = 3.5, 8.6 Hz, H-3'), 3.87 (t, 1H, *J* = 9.3 Hz, H-4), 3.65–3.77 (m, 3H, H-5, H-6), 3.59 (s, 3H, CH₃ CO₂Me), 3.55–3.57 (m, 1H, H-2), 3.52 (t, 1H, *J* = 3.4 Hz, H-2'), 3.39 (s, 3H, OMe), 2.09 (s, 3H, CH₃ Ac); HRMS [M + Na]⁺ calcd for C₃₇H₄₂N₆O₁₁Na 769.28038, found 769.28022.

p-Methoxyphenyl 3-O-(Methyl 4-O-acetyl-2,3-diazido-2,3-dideoxy- α/β -D-mannopyranosyl uronate)-2-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (31). Donor **8 β** and acceptor **22** were condensed using the general protocol for Ph₂SO/Tf₂O-mediated glycosylations to yield disaccharide **31** (89%, α/β = 1:7.5). TLC *R_f* α 0.55, β 0.45 (toluene/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 1057, 1219, 1504, 1751, 2106. Spectroscopic data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.52–7.56 (m, 2H, CH_{arom}), 7.28–7.44 (m, 8H, CH_{arom}), 7.06 (d, 2H, *J* = 9.1 Hz, CH_{arom}), 6.83 (d, 1H, *J* = 9.1 Hz, CH_{arom}), 5.59 (s, 1H, CH Ph), 5.13 (t, 1H, *J* = 10.0 Hz, H-4'), 5.09 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.87–4.89 (m, 2H, H-1, H-1'), 4.66 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.32–4.38 (m, 2H, H-4, H-6), 4.18 (dd, 1H, *J* = 7.8, 9.9 Hz, H-2), 4.07 (dd, 1H, *J* = 1.4, 12.4 Hz, H-6), 3.88 (dd, 1H, *J* = 3.5, 9.9 Hz, H-3), 3.78 (s, 3H, OMe), 3.72 (s, 3H, CH₃ CO₂Me), 3.69 (d, 1H, *J* = 9.7 Hz, H-5'), 3.50 (s, 1H, H-5), 3.32 (d, 1H, *J* = 3.3 Hz, H-2') 3.02 (dd, 1H, *J* = 3.5, 10.2 Hz, H-3'), 2.07 (s, 3H, CH₃ Ac); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 169.2, 166.9 (C=O Ac, CO₂Me), 155.3, 151.3, 138.6, 137.6 (C_q Ph, Bn), 128.7, 128.6, 128.3, 128.2, 127.8, 126.3, 126.2, 118.5, 114.4 (CH_{arom}), 103.0 (C-1), 100.6 (C-1'), 100.4 (CH Ph), 79.2 (C-2), 77.0 (C-3), 75.4 (CH₂ Bn), 75.4 (C-4), 73.5 (C-5'), 68.7 (C-6), 67.4 (C-4'), 66.5 (C-5), 61.6 (C-2'), 61.0 (C-3'), 55.5 (OMe), 52.8 (CH₃ CO₂Me), 22.4 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 103.0 (*J*_{C1,H1} = 158 Hz, C-1), 100.6 (*J*_{C1,H1} = 161 Hz, C-1'); HRMS [M + Na]⁺ calcd for C₃₆H₃₈N₆O₁₂Na 769.24399, found 769.24405.

3,4,6-Tri-O-acetyl-2-azido-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-glucopyranoside (36). Compound **35**^{26a,b} (0.95 g, 2.87 mmol) was dissolved in acetone (25 mL), followed by the addition of N-(phenyl)trifluoroacetimidoyl chloride³⁴ (0.87 mL, 5.73 mmol), K₂CO₃ (0.48 g, 3.44 mmol), and H₂O (1 mL). After stirring for 1.5 h at rt, the mixture was diluted with EtOAc and the organic layer was washed with saturated aqueous NaCl (2 \times), dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 33% EtOAc in PE) yielded the title product as a yellowish oil (1.38 g, 2.76 mmol, 96%, α/β = 1.4:1); TLC *R_f* 0.65 (PE/EtOAc, 2/1, v/v); IR (neat, cm⁻¹) 727, 907, 1209, 1747, 2114; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, T = 328 K) δ 7.27–7.33 (m, 4.8H, CH_{arom}), 7.09–7.15 (m, 2.4H, CH_{arom}), 6.82–6.87 (m, 4.8H, CH_{arom}), 6.43 (d, 1.4H, *J* = 2.6 Hz, H-1 α), 5.59 (d, 1H, *J* = 8.2 Hz, H-1 β), 5.48 (t, 1.4H, *J* = 9.9 Hz, H-3 α), 5.11 (t, 1.4H, *J* = 9.7 Hz, H-4 α), 5.00–5.08 (m, 2H, H-3 β , H-4 β), 4.21–4.30 (m, 2.4H, H-6 α , H-6 β), 4.07–4.14 (m, 3.8H, H-5 α , H-6 α , H-6 β), 3.69–3.76 (m, 2.4H, H-2 α , H-2 β), 3.63–3.69 (m, 1H, H-5 β), 2.09 (s, 4.2H, CH₃ Ac- α), 2.08 (s, 3H, CH₃ Ac- β), 2.06 (s, 4.2H, CH₃ Ac- α), 2.04 (s, 7.2H, CH₃ Ac- α , CH₃ Ac- β), 1.99 (s, 3H, CH₃ Ac- β); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.0, 169.9, 169.4, 169.4, 169.2,

169.1 (C=O Ac), 142.6 (C_q Ph), 128.6, 124.4, 118.9, 118.8 (CH_{arom}), 115.6 (q, *J* = 284 Hz, CF₃), 155.5 (q, *J* = 283 Hz, CF₃), 94.9 (C-1β), 92.8 (C-1α), 72.3, 72.1 (C-4), 70.2, 69.8 (C-3, C-5), 67.5, 67.5 (C-3, C-5), 62.4 (C-2), 61.1 (C-6, C-6), 60.1 (C-2), 20.1, 20.1, 20.5, 20.0 (CH₃ Ac); HRMS [M(hemiacetal)+Na]⁺ calcd for C₁₂H₁₇N₃O₈Na 354.09079, found 354.09059.

***N*-(Benzyl)benzyloxycarbonyl-5-aminopentyl O-3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranoside (37).** Donor **36** (0.52 g, 1.04 mmol) and *N*-(benzyl)benzyloxycarbonyl-5-aminopentanol (0.51 g, 1.56 mmol) were together coevaporated with toluene (2×), dissolved in dry Et₂O (21 mL), and stirred on activated MS for 30 min at rt. The solution was cooled to -40 °C, and TfOH (18 μL, 0.21 mmol) was added. The mixture was allowed to warm to -10 °C in 1 h followed by the addition of Et₃N (0.1 mL). EtOAc was added, and the organic phase was washed with saturated aqueous NaCl (2×), dried over Na₂SO₄, and concentrated in vacuo. The residue was dissolved in pyridine (6 mL) and treated with Ac₂O (2 mL) for 2 h, followed by the addition of EtOAc. The solution was washed with saturated aqueous NaCl (2×), dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 50% EtOAc in PE) gave the title compound as a yellowish oil (0.64 g, 0.99 mmol, 95%, α/β = 7.4:1). TLC R_f 0.41 (PE/EtOAc, 3/2, v/v); IR (neat, cm⁻¹) 698, 1030, 1219, 1694, 1746, 2108, 2922. Spectroscopic data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.13–7.40 (m, 10H, CH_{arom}), 5.47 (t, 1H, *J* = 9.9 Hz, H-3), 5.18 (d, 2H, *J* = 13.1 Hz, CH₂ Z), 5.04 (t, 1H, *J* = 9.8 Hz, H-4), 4.93 (d, 1H, *J* = 12.0 Hz, H-1), 4.50 (bs, 2H, CH₂ Bn), 4.28 (dd, 1H, *J* = 3.5, 12.2 Hz, H-6), 4.06 (d, 1H, *J* = 12.5 Hz, H-6), 3.94–4.02 (m, 1H, H-5), 3.60–3.75 (m, 1H, CH₂), 3.35–3.50 (m, 1H, CH₂), 3.26 (dd, 1H, *J* = 3.5, 10.6 Hz, H-2), 3.18–3.30 (m, 2H, CH₂), 2.08 (s, 3H, CH₃ Ac), 2.07 (s, 3H, CH₃ Ac), 2.03 (s, 3H, CH₃ Ac), 1.45–1.70 (m, 4H, CH₂), 1.24–1.42 (m, 2H, CH₂); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 170.2, 169.7, 169.3 (C=O Ac), 156.1 (d, *J* = 50 Hz, C=O Z), 137.7 (C_q Z), 136.6 (d, *J* = 10 Hz, C_q Bn), 128.3, 127.6, 127.0 (CH_{arom}), 97.5 (C-1), 70.0 (C-3), 68.3 (C-4), 68.3 (CH₂), 67.3 (C-5), 66.8 (CH₂ Z), 61.6 (C-6), 60.5 (C-2), 50.1 (d, *J* = 32 Hz, CH₂ Bn), 46.3 (d, *J* = 91 Hz, CH₂), 28.7 (CH₂), 27.3 (d, *J* = 48 Hz, CH₂), 23.0 (CH₂), 20.4, 20.3 (CH₃ Ac); ¹³C-GATED (CDCl₃, 100 MHz) δ 97.5 (*J*_{C1,H1} = 171 Hz, C-1). Diagnostic peak for the β-anomer: ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 101.7 (C-1); HRMS [M + Na]⁺ calcd for C₃₂H₄₀N₄O₁₀Na 663.26366, found 663.26356.

***N*-(Benzyl)benzyloxycarbonyl-5-aminopentyl O-2-Azido-2-deoxy-α-D-glucopyranoside (38).** Compound **37** (0.64 g, 0.99 mmol) was dissolved in MeOH (10 mL) and treated with NaOMe (cat.) for 4 h until full consumption of the starting material was indicated by TLC analysis. The mixture was neutralized by the addition of Amberlite-H⁺, filtered, and concentrated in vacuo. The title compound was used in the next reaction step without further purification. TLC R_f 0.18 (PE/EtOAc, 1/3, v/v); IR (neat, cm⁻¹) 1028, 1682, 2106, 2930, 3552. Spectroscopic data for the α-anomer: ¹H NMR (MeOH-*d*₄, 400 MHz, HH-COSY, HSQC) δ 7.64–7.71 (m, 2H, CH_{arom}), 7.08–7.33 (m, 8H, CH_{arom}), 5.10 (d, 1H, *J* = 17.1 Hz, CH₂ Z), 4.80 (bs, 1H, H-1), 4.43 (bs, 2H, CH₂ Bn), 3.85 (t, 1H, *J* = 9.5 Hz, H-3), 3.77 (d, 1H, *J* = 11.9 Hz, H-6), 3.69 (dd, 1H, *J* = 5.0, 11.9 Hz, H-6), 3.49–3.64 (m, 2H, H-5, CH₂), 3.36 (t, 1H, *J* = 9.3 Hz, H-4), 3.25–3.32 (m, 1H, CH₂), 3.12–3.24 (m, 2H, CH₂), 3.02 (dd, 1H, *J* = 2.9, 10.4 Hz, H-2), 1.39–1.60 (m, 4H, CH₂), 1.20–1.38 (m, 2H, CH₂); ¹³C-APT NMR (MeOH-*d*₄, 100 MHz, HSQC) δ 157.8 (d, *J* = 53 Hz, C=O Z), 138.7 (d, *J* = 9 Hz, C_q Z), 137.5 (d, *J* = 11 Hz, C_q Bn), 129.3, 128.6, 128.4, 128.1, 128.0 (CH_{arom}), 99.0 (C-1), 73.3 (C-5), 72.1 (C-3), 71.7 (C-4), 68.5, 68.2 (CH₂, CH₂ Z), 64.0 (C-2), 62.1 (C-6), 51.2 (d, *J* = 19 Hz, CH₂ Bn), 47.6 (d, *J* = 88 Hz, CH₂), 29.8 (CH₂), 28.4 (d, *J* = 46 Hz, CH₂), 24.1 (CH₂). Diagnostic peak for the β-anomer: ¹³C-APT NMR (MeOH-*d*₄, 100 MHz, HSQC) δ 102.9 (C-1); HRMS [M + Na]⁺ calcd for C₂₆H₃₂N₄O₇Na 537.23197, found 537.23153.

***N*-(Benzyl)benzyloxycarbonyl-5-aminopentyl O-2-Azido-4,6-O-di-*tert*-butylsilylidene-2-deoxy-α-D-glucopyranoside (39).**

Compound **38** (0.52 mmol) was coevaporated with toluene (2×) and dissolved in dry DMF (5 mL) under an argon atmosphere. The solution was cooled to -40 °C, and di-*tert*-butylsilylbis(triflate) (0.19 mL, 0.6 mmol) was dropwise added. The reaction was stirred for 1.5 h, followed by the addition of pyridine (0.2 mL). The mixture was diluted with EtOAc, washed with saturated aqueous NaCl (2×), dried over Na₂SO₄, filtered, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 14% EtOAc in PE) gave the title compound as a colorless oil (0.26 g, 0.39 mmol, 76%): TLC R_f 0.64 (PE/EtOAc, 3/1, v/v); [α]_D²⁰ +52.2 (c 1, DCM); IR (neat, cm⁻¹) 827, 1088, 1688, 2108, 2858, 2934, 3429; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, T = 328 K) δ 7.16–7.34 (m, 10H, CH_{arom}), 5.17 (s, 2H, CH₂ Z), 4.75 (d, 1H, *J* = 3.4 Hz, H-1), 4.48 (s, 2H, CH₂ Bn), 4.07 (dd, 1H, *J* = 4.6, 9.6 Hz, H-6), 3.97 (dd, 1H, *J* = 8.6, 10.1 Hz, H-3), 4.83 (t, 1H, *J* = 10.0 Hz, H-6), 3.75 (ddd, 1H, *J* = 4.5, 9.4, 9.4 Hz, H-5), 3.65 (t, 1H, *J* = 8.8 Hz, H-4), 3.57–3.63 (m, 1H, CH₂), 3.36–3.44 (m, 1H, CH₂), 3.18–3.27 (m, 1H, CH₂), 3.14 (dd, 1H, *J* = 3.6, 10.2 Hz, H-2), 2.85 (bs, 1H, 3-OH), 1.48–1.62 (m, 4H, CH₂), 1.25–1.38 (m, 2H, CH₂), 1.06 (s, 9H, CH₃tBu), 0.99 (s, 9H, CH₃tBu); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 156.3 (d, *J* = 48 Hz, C=O Z), 137.7, 136.7 (C_q Bn), 128.4, 128.3, 127.8, 127.7, 127.1 (CH_{arom}), 98.0 (C-1), 77.9 (C-4), 71.3 (C-3), 68.1 (CH₂), 67.0 (CH₂ Z), 66.3 (C-6), 66.0 (C-5), 62.1 (C-2), 50.3 (d, *J* = 30 Hz, CH₂ Bn), 46.5 (d, *J* = 95 Hz, CH₂), 28.9, 27.7 (CH₂), 27.3, 26.8 (CH₃tBu), 23.3 (CH₂), 22.5, 19.8 (C_qtBu); HRMS [M + Na]⁺ calcd for C₃₄H₅₀N₄O₇SiNa 677.33410, found 677.33397.

Methyl (Phenyl 4-O-[2,3,4-tri-O-benzyl-6-O-{9-fluorenylmethoxycarbonyl}-α-D-glucopyranosyl]-2,3-diazido-2,3-dideoxy-1-thio-β-D-mannopyranosyl Uronate) (41). Imidate **40**^{3b} (0.55 g, 0.65 mmol) and acceptor **16β** (0.18 g, 0.5 mmol) were together coevaporated with dry toluene (2×). Et₂O (13 mL, dried over 4 Å MS prior to use) was added, and the mixture was cooled to -40 °C. TfOH (9 μL, 0.1 mmol) was added, and the mixture was allowed to warm to -10 °C. Then pyridine (0.1 mL) was added, and the mixture was diluted with EtOAc and washed with saturated aqueous NaCl (2×). The organic layer was dried over Na₂SO₄, concentrated in vacuo, and purified using column chromatography (silica gel, 20% EtOAc in PE) to yield the title compound as a colorless oil (0.48 g, 0.48 mmol, 96%): TLC R_f 0.54 (PE/EtOAc, 3/1, v/v); [α]_D²⁰ +36.6 (c 1, DCM); IR (neat, cm⁻¹) 696, 737, 1070, 1252, 1744, 2106; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.75 (d, 2H, *J* = 7.6 Hz, CH_{arom}), 7.59 (dd, 2H, *J* = 7.6, 11.1 Hz, CH_{arom}), 7.20–7.45 (m, 24H, CH_{arom}), 5.00 (d, 1H, *J* = 3.9 Hz, H-1'), 4.99 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.89 (d, 1H, *J* = 4.89 Hz, CHH Bn), 4.67–4.81 (m, 4H, CHH Bn, CH₂ Bn, H-1), 4.57 (d, 1H, *J* = 10.8 Hz, CHH Bn), 4.33–4.44 (m, 3H, CH₂ Fmoc, H-6'), 4.30 (dd, 1H, *J* = 2.5, 11.9 Hz, H-6'), 4.22 (t, 1H, *J* = 7.3 Hz, CH Fmoc), 4.12–4.17 (m, 2H, H-2, H-4), 3.94 (t, 1H, *J* = 9.4 Hz, H-3'), 3.80 (d, 1H, *J* = 9.4 Hz, H-5), 3.72–3.77 (m, 4H, H-5', CH₃ CO₂Me), 3.70 (dd, 1H, *J* = 3.5, 9.8 Hz, H-3), 3.60 (t, 1H, *J* = 9.5 Hz, H-4'), 3.52 (dd, 1H, *J* = 3.3, 9.8 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 166.7 (C=O CO₂Me), 154.8 (C=O Fmoc), 143.3, 143.1, 141.1 (C_q Fmoc), 138.5, 137.9, 137.8 (C_q Bn), 133.2 (C_q SPh), 131.3, 129.2, 128.3, 127.9, 127.8, 127.6, 127.1, 125.0, 125.0, 119.9 (CH_{arom}), 99.6 (C-1'), 87.3 (C-1), 81.0 (C-3'), 79.9, 79.9 (C-2', C-5), 76.5, 76.3 (C-4, C-4'), 75.5, 75.1, 73.5 (CH₂ Bn), 70.1 (C-5'), 69.7 (CH₂ Fmoc), 65.8 (C-3), 65.7 (C-6'), 64.4 (C-2), 52.9 (CH₃ CO₂Me), 46.6 (CH Fmoc); ¹³C-GATED (CDCl₃, 100 MHz) δ 99.6 (*J*_{C1,H1} = 172 Hz, C-1'), 87.3 (*J*_{C1,H1} = 155 Hz, C-1); HRMS [M + Na]⁺ calcd for C₅₅H₅₂N₆O₁₁SiNa 1027.33070, found 1027.33138.

***N*-(Benzyl)benzyloxycarbonyl-5-aminopentyl O-(Methyl 4-O-[2,3,4-tri-O-benzyl-6-O-{9-fluorenylmethoxycarbonyl}-α-D-glucopyranosyl]-2,3-diazido-2,3-dideoxy-β-D-mannopyranosyl Uronate)-2-azido-4,6-O-di-*tert*-butylsilylidene-2-deoxy-α-D-glucopyranoside (42).** Compound **41** (0.29 g, 0.29 mmol) and Ph₂SO (70 mg, 0.35 mmol) were together coevaporated with toluene (2×). Freshly distilled DCM (5.8 mL) and activated molecular sieves (3 Å)

were added under an argon atmosphere, and the resulting mixture was stirred at rt for 20 min, followed by cooling to -80°C . Te_2O (59 μL , 0.35 mmol) was added, and the mixture was allowed to warm to -60°C in 15 min. After cooling back to -80°C , a solution of compound **39** (0.26 g, 0.39 mmol) in DCM (2 mL) was added. The reaction was warmed to -10°C in 4 h, after which time pyridine (0.2 mL) was added. The mixture was diluted with EtOAc, washed with saturated aqueous NaCl (2 \times), dried over Na_2SO_4 , filtered, and concentrated in vacuo. Purification by size-exclusion chromatography (Sephadex LH-20, eluted with DCM/MeOH, 1/1, v/v) gave the title compound as a colorless oil (0.45 g, 0.29 mmol, >98%): TLC R_f 0.36 (PE/EtOAc, 3/1, v/v); $[\alpha]_{\text{D}}^{20} +30.8$ (c 1, DCM); IR (neat, cm^{-1}) 698, 739, 1043, 1072, 1094, 1256, 1697, 1749, 2108, 2934; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, $T = 328\text{ K}$) δ 7.71 (d, 2H, $J = 7.6$ Hz, CH_{arom}), 7.57 (t, 2H, $J = 7.6$ Hz, CH_{arom}), 7.18–7.40 (m, 29H, CH_{arom}), 5.17 (s, 2H, CH_2Z), 5.09 (d, 1H, $J = 3.1$ Hz, H-1''), 4.97 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.92 (s, 1H, H-1'), 4.87 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.78 (d, 2H, $J = 11.4$ Hz, H-1, CHH Bn), 4.70–4.75 (m, 2H, CH_2Bn), 4.58 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.49 (s, 2H, CH_2Bn), 4.35–4.42 (m, 3H, H-6'', CH_2Fmoc), 4.31 (dd, 1H, $J = 2.1, 11.8$ Hz, H-6''), 4.21 (t, 1H, $J = 7.5$ Hz, CH Fmoc), 4.16 (t, 1H, $J = 9.4$ Hz, H-4'), 4.01–4.08 (m, 2H, H-2', H-6), 3.89–3.96 (m, 2H, H-3, H-3'), 3.78–3.89 (m, 3H, H-4, H-5', H-6), 3.69–3.78 (m, 2H, H-5, H-5''), 3.67 (s, 3H, $\text{CH}_3\text{CO}_2\text{Me}$), 3.55–3.62 (m, 2H, H-4'', CHH CH_2), 3.48–3.54 (m, 2H, H-2'', H-3'), 3.36–3.45 (m, 1H, CHH CH_2), 3.27 (dd, 1H, $J = 3.4, 10.1$ Hz, H-2), 3.20–3.26 (m, 2H, CH_2), 1.48–1.64 (m, 4H, CH_2), 1.26–1.38 (m, 2H, CH_2), 1.04 (s, 9H, CH_3tBu), 0.97 (s, 9H, CH_3tBu); ^{13}C -APT NMR (CDCl_3 , 100 MHz, HSQC) δ 166.9 (C=O CO_2Me), 156.3 (d, $J = 50$ Hz, C=O Z), 154.8 (C=O Fmoc), 143.3, 143.1, 141.1, 141.1 (C_q Fmoc), 138.5, 137.8, 137.8, 137.7 (C_q Bn), 136.7 (d, $J = 17$ Hz, C_q Bn), 128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.5, 127.2, 127.0 (CH_{arom}), 125.0, 124.9, 119.9 (CH_{arom} Fmoc), 101.0 (C-1'), 99.1 (C-1''), 97.4 (C-1), 80.9 (C-3''), 79.7 (C-2''), 79.4 (C-3), 76.7 (C-5'), 76.4 (C-4''), 76.0 (C-4), 75.5 (C-4'), 75.4, 75.0, 73.3 (CH_2Bn), 69.9 (C-5''), 69.7 (CH_2Fmoc), 68.1 (CH_2), 67.0 (CH_2Z), 66.6 (C-5), 66.3 (C-6), 65.6 (C-6''), 63.4 (C-3'), 62.6 (C-2'), 62.5 (C-2), 52.6 ($\text{CH}_3\text{CO}_2\text{Me}$), 50.3 (d, $J = 24$ Hz, CH_2Bn), 46.6 (CH Fmoc), 46.4 (d, $J = 109$ Hz, CH_2), 28.8 (CH_2), 27.5 (d, $J = 33$ Hz, CH_2), 27.2, 26.8 (CH_3tBu), 23.3 (CH_2), 22.5, 19.7 (C_qtBu); ^{13}C -GATED (CDCl_3 , 100 MHz) δ 101.0 ($J_{\text{C}_1, \text{H}_1} = 158$ Hz, C-1'), 99.1 ($J_{\text{C}_1, \text{H}_1} = 170$ Hz, C-1''), 97.4 ($J_{\text{C}_1, \text{H}_1} = 170$ Hz, C-1); HRMS [$\text{M} + \text{NH}_4$] $^+$ calcd for $\text{C}_{83}\text{H}_{100}\text{N}_{11}\text{O}_{18}\text{Si}$ 1566.70116, found 1566.70311.

N-(Benzyl)benzyloxycarbonyl-5-aminopentyl O-(Methyl 4-O-[2,3,4-tri-O-benzyl- α -D-glucopyranosyl]-2,3-diazido-2,3-dideoxy- β -D-mannopyranosyl Uronate)-2-azido-4,6-O-di-tert-butylsilylidene-2-deoxy- α -D-glucopyranoside (43). Compound **42** (0.39 g, 0.25 mmol) was dissolved in pyridine (5 mL) and treated with triethylamine (0.53 mL, 3.79 mmol) for 3 h, followed by addition of EtOAc. The organic phase was washed with H_2O (1 \times) and saturated aqueous NaCl (2 \times), dried over Na_2SO_4 , filtered, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 33% EtOAc in PE) furnished the title compound as a colorless oil (0.32 g, 0.24 mmol, 94%): TLC R_f 0.36 (PE/EtOAc, 2/1, v/v); $[\alpha]_{\text{D}}^{20} +18.8$ (c 1, DCM); IR (neat, cm^{-1}) 1028, 1072, 1686, 1751, 2108, 2858, 2934; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, $T = 328\text{ K}$) δ 7.18–7.40 (m, 25H, CH_{arom}), 5.17 (s, 2H, CH_2Z), 5.00 (d, 1H, $J = 3.4$ Hz, H-1''), 4.93 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.91 (d, 1H, $J = 0.8$ Hz, H-1'), 4.84 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.81 (d, 1H, $J = 3.3$ Hz, H-1), 4.77 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.71 (s, 2H, CH_2Bn), 4.60 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.50 (bs, 2H, CH_2Bn), 4.14 (t, 1H, $J = 9.4$ Hz, H-4'), 4.05 (dd, 1H, $J = 4.6, 9.8$ Hz, H-6), 4.02 (d, 1H, $J = 3.1$ Hz, H-2'), 3.78–3.93 (m, 5H, H-3, H-3'', H-5', H-5'', H-6), 3.70–3.78 (m, 2H, H-5, H-6''), 3.66 (s, 3H, $\text{CH}_3\text{CO}_2\text{Me}$), 3.55–3.64 (m, 3H, H-4, H-6'', CHH CH_2), 3.53 (dd, 1H, $J = 3.3, 9.7$ Hz, H-3'), 3.35–3.47 (m, 3H, H-2'', H-4'', CHH CH_2), 3.28 (dd, 1H, $J = 3.5, 10.0$ Hz, H-2), 3.20–3.27 (m, 2H, CH_2), 2.02 (bs, 1H, 6''-OH), 1.48–1.63 (m, 4H, CH_2), 1.25–1.38 (m, 2H, CH_2), 1.04 (s, 9H, CH_3tBu),

0.97 (s, 9H, CH_3tBu); ^{13}C -APT NMR (CDCl_3 , 100 MHz, HSQC) δ 167.1 (C=O CO_2Me), 156.2 (d, $J = 53$ Hz, C=O Z), 138.5, 137.9, 137.7 (C_q Bn), 136.6 (d, $J = 17$ Hz, C_q Bn), 128.4, 128.3, 128.2, 127.8, 127.6, 127.4, 127.1, 127.0 (CH_{arom}), 100.9 (C-1'), 98.7 (C-1''), 97.3 (C-1), 80.8 (C-3''), 79.7 (C-2''), 79.4 (C-3), 77.2 (C-4''), 76.8 (C-5'), 75.9 (C-5''), 75.4 (CH_2Bn), 74.9 (C-4'), 74.9, 73.3 (CH_2Bn), 72.6 (C-4), 68.0 (CH_2), 67.0 (CH_2Z), 66.5 (C-5), 66.3 (C-6), 63.1 (C-3'), 62.5 (C-2'), 62.4 (C-2), 61.4 (C-6''), 52.5 ($\text{CH}_3\text{CO}_2\text{Me}$), 50.2 (d, $J = 25$ Hz, CH_2Bn), 46.4 (d, $J = 108$ Hz, CH_2), 28.8 (CH_2), 27.4 (d, $J = 34$ Hz, CH_2), 27.1, 26.8 (CH_3tBu), 23.2 (d, $J = 11$ Hz, CH_2), 22.4, 19.6 (C_qtBu); ^{13}C -GATED (CDCl_3 , 100 MHz) δ 100.9 ($J_{\text{C}_1, \text{H}_1} = 160$ Hz, C-1'), 98.7 ($J_{\text{C}_1, \text{H}_1} = 169$ Hz, C-1''), 97.3 ($J_{\text{C}_1, \text{H}_1} = 170$ Hz, C-1); HRMS [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{68}\text{H}_{86}\text{N}_{10}\text{O}_{16}\text{SiNa}$ 1349.58847, found 1349.58962.

Methyl (Phenyl 2,3-diazido-4-O-tert-butylidimethylsilyl-2,3-dideoxy-1-thio- β -D-mannopyranosyl Uronate) (44). Compound **16 β** (0.35 g, 1.0 mmol) was dissolved in dry DCM (20 mL) and cooled to 0°C , followed by the addition of Et_3N (0.84 mL, 6 mmol) and TBS-OTf (0.45 mL, 2 mmol). The resulting solution was stirred overnight at rt. Saturated aqueous NaHCO_3 was added, and the mixture was diluted with EtOAc. The organic fraction was separated, washed with saturated aqueous NaCl (2 \times), dried over Na_2SO_4 , and concentrated in vacuo. Purification using flash column chromatography (silica gel, 10% EtOAc in PE) yielded the title compound as amorphous white solids (0.41 g, 0.88 mmol, 88%): TLC R_f 0.67 (PE/EtOAc, 4/1, v/v); $[\alpha]_{\text{D}}^{20} -10.6$ (c 1, DCM); IR (neat, cm^{-1}) 827, 1057, 1441, 1742, 2106, 2927; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC) δ 7.38–7.43 (m, 2H, CH_{arom}), 7.24–7.30 (m, 3H, CH_{arom}), 4.87 (s, 1H, H-1), 4.20 (d, 1H, $J = 3.2$ Hz, H-2), 4.04 (t, 1H, $J = 9.3$ Hz, H-4), 3.78 (d, 1H, $J = 9.2$ Hz, H-5), 3.73 (s, 3H, $\text{CH}_3\text{CO}_2\text{Me}$), 3.56 (dd, 1H, $J = 3.5, 9.5$ Hz, H-3), 0.83 (s, 9H, CH_3tBu), 0.18 (s, 3H, CH_3Me), 0.01 (s, 3H, CH_3Me); ^{13}C -APT NMR (CDCl_3 , 100 MHz, HSQC) δ 167.3 (C=O CO_2Me), 133.4 (C_q Sph), 131.2, 129.1, 127.9 (CH_{arom}), 87.2 (C-1), 80.8 (C-5), 68.1 (C-3), 67.6 (C-2), 64.8 (C-4), 52.4 ($\text{CH}_3\text{CO}_2\text{Me}$), 25.5 (CH_3tBu), 17.8 (C_qtBu), -4.8, -5.3 (C_qMe); ^{13}C -GATED (CDCl_3 , 100 MHz) δ 87.2 ($J_{\text{C}_1, \text{H}_1} = 155$ Hz, C-1); HRMS [$\text{M} + \text{NH}_4$] $^+$ calcd for $\text{C}_{19}\text{H}_{32}\text{N}_7\text{O}_4\text{SSi}$ 482.20003, found 482.20002.

N-(Benzyl)benzyloxycarbonyl-5-aminopentyl 3-O-(Methyl 4-O-[6-O-{methyl 2,3-diazido-4-O-tert-butylidimethylsilyl-2,3-dideoxy- β -D-mannopyranosyl Uronate}-2,3,4-tri-O-benzyl- α -D-glucopyranosyl]-2,3-diazido-2,3-dideoxy- β -D-mannopyranosyl Uronate)-2-azido-4,6-O-di-tert-butylsilylidene-2-deoxy- α -D-glucopyranoside (45). Compound **44** (30 mg, 65 μmol), Ph_2SO (13 mg, 65 μmol), and TTBP (32 mg, 130 μmol) were together coevaporated with toluene (2 \times). Freshly distilled DCM (1.5 mL) and activated molecular sieves (3 \AA) were added under an argon atmosphere, and the resulting mixture was stirred at rt for 20 min, followed by cooling to -80°C . Te_2O (11 μL , 65 μmol) was added, and the mixture was stirred at -80°C for 20 min. Then a solution of compound **43** (95 mg, 71 μmol) in DCM (1 mL) was added. The reaction was stirred overnight at -30°C and subsequently warmed to -10°C , followed by the addition of triethylamine (0.1 mL). The mixture was diluted with EtOAc, washed with saturated aqueous NaCl (2 \times), dried over Na_2SO_4 , filtered, and concentrated in vacuo. Purification by flash column chromatography (silica gel, 20% EtOAc in PE) and subsequent size-exclusion chromatography (Sephadex LH-20, eluted with DCM/MeOH, 1/1, v/v) to remove hydrolyzed donor gave the title compound as a colorless oil (81 mg, 48 μmol , 74%): TLC R_f 0.33 (PE/EtOAc, 4/1, v/v); $[\alpha]_{\text{D}}^{20} +10.9$ (c 1, DCM); IR (neat, cm^{-1}) 696, 727, 907, 1692, 1751, 2106, 2931; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, $T = 328\text{ K}$, tentatively assigned based on ^1H NMR of compound **42**) δ 7.13–7.36 (m, 25H, CH_{arom}), 5.15 (s, 2H, CH_2Z), 5.02 (d, 1H, $J = 3.4$ Hz, H-1''), 4.92 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.87 (s, 1H, H-1'), 4.76–4.83 (m, 2H, H-1, CHH Bn), 4.72 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.63–4.69 (m, 2H, CH_2Bn), 4.58 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.47

(s, 2H, CH₂ Bn), 4.32 (s, 1H, H-1'''), 4.07 (t, 1H, J = 9.5 Hz, H-4'), 3.96–4.03 (m, 2H, H-2', H-6), 3.89–3.96 (m, 2H, H-4''', H-6''), 3.75–3.89 (m, 5H, H-3, H-3'', H-5', H-5'', H-6), 3.65–3.75 (m, 5H, H-2''', H-5, CH₃ CO₂Me), 3.54–3.64 (m, 7H, H-4, H-5''', H-6'', CH₂, CH₃ CO₂Me), 3.43–3.48 (m, 2H, H-3', H-4''), 3.35–3.42 (m, 2H, H-2'', CH₂), 3.26 (dd, 1H, J = 3.6, 9.9 Hz, H-2), 3.17–3.24 (m, 2H, CH₂), 3.12 (dd, 1H, J = 3.5, 9.5 Hz, H-3'''), 1.46–1.63 (m, 4H, CH₂), 1.25–1.37 (m, 2H, CH₂), 1.01 (s, 9H, CH₃tBu), 0.94 (s, 9H, CH₃tBu), 0.83 (s, 9H, CH₃tBu), 0.14 (s, 3H, CH₃ Me), –0.03 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC, tentatively assigned based on ¹³C-APT NMR of compound 42) δ 167.7, 167.0 (C=O CO₂Me), 156.3 (d, J = 53 Hz, C=O Z), 138.6, 138.5, 137.9, 137.8 (C_q Bn), 136.7 (d, J = 18 Hz, C_q Bn), 128.3, 127.9, 127.8, 127.7, 127.5, 127.1 (CH_{arom}), 101.0 (C-1'), 100.0 (C-1'''), 98.8 (C-1''), 97.4 (C-1), 81.1 (C-3'), 79.6 (C-2'', C-3), 77.5 (C-5'''), 76.9 (C-5''), 76.0, 75.9 (C-4'', C-5'), 75.3 (CH₂ Bn), 74.7 (C-4'), 74.4, 73.4 (CH₂ Bn), 70.9 (C-4), 68.2 (CH₂), 67.7 (C-4'''), 67.2, 67.1 (C-6'', CH₂ Z), 66.6 (C-5), 66.4 (C-6), 64.9 (C-3'''), 63.3 (C-3'), 62.7 (C-2'), 62.5, 62.4 (C-2, C-2'''), 52.7, 52.3 (CH₃ CO₂Me), 50.3 (d, J = 26 Hz, CH₂ Bn), 46.5 (d, J = 107 Hz, CH₂), 28.9 (d, J = 7 Hz, CH₂), 27.5 (d, J = 35 Hz, CH₂), 27.2, 26.9, 25.5 (CH₃tBu), 23.3 (d, J = 10 Hz, CH₂), 22.5, 19.7, 17.9 (C_qtBu), –4.7, –5.3 (CH₃ Me); ¹³C-GATED (CDCl₃, 100 MHz) δ 101.0 (J_{C1,H1} = 157 Hz, C-1'), 100.0 (J_{C1,H1} = 160 Hz, C-1'''), 98.8 (J_{C1,H1} = 168 Hz, C-1''), 97.4 (J_{C1,H1} = 169 Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₈₁H₁₁₂N₁₇O₂₀Si₂ 1698.78026, found 1698.78165.

N-(Benzyl)benzyloxycarbonyl-5-aminopentyl 3-O-(Methyl-4-O-[6-O-{methyl 2,3-diazido-2,3-dideoxy-β-D-mannopyranosyl Uronate}-2,3,4-tri-O-benzyl-α-D-glucopyranosyl]-2,3-diazido-2,3-dideoxy-β-D-mannopyranosyl Uronate)-2-azido-2-deoxy-α-D-glucopyranoside (46). A solution of compound 45 (69 mg, 41 μmol) in THF (1 mL) was cooled to 0 °C and treated with acetic acid (9 μL, 0.16 mmol) and tetrabutylammonium fluoride (1 M in THF, 82 μL, 82 μmol). The resulting solution was stirred for 3 h, followed by the addition of H₂O and EtOAc. The organic phase was washed with saturated aqueous NaCl (2×), dried over Na₂SO₄, concentrated in vacuo, and purified using flash column chromatography (silica gel, 50% EtOAc in PE) to yield the 4'''-OTBS-protected intermediate as a colorless oil (60 mg, 39 μmol, 96%). Spectroscopic data are reported for the 4'''-OTBS-protected intermediate: TLC R_f 0.44 (PE/EtOAc, 1/1, v/v); ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, T = 328 K) δ 7.19–7.41 (m, 25H, CH_{arom}), 5.20 (s, 2H, CH₂ Z), 5.06 (d, 1H, J = 3.3 Hz, H-1''), 4.97 (d, 1H, J = 11.1 Hz, CHH Bn), 4.83–4.93 (m, 3H, CHH Bn, H-1, H-1'), 4.78 (d, 1H, J = 11.3 Hz, CHH Bn), 4.75 (d, 1H, J = 11.9 Hz, CHH Bn), 4.69 (d, 1H, J = 11.7 Hz, CHH Bn), 4.63 (d, 1H, J = 11.8 Hz, CHH Bn), 4.52 (s, 2H, CH₂ Bn), 4.33 (s, 1H, H-1'''), 4.16 (t, 1H, J = 8.7 Hz, H-4'), 4.10 (d, 1H, J = 1.2 Hz, H-2'), 4.05 (d, 1H, J = 8.4 Hz, H-5'), 3.85–4.02 (m, 4H, H-3, H-3'', H-6, H-6''), 3.77–3.82 (m, 1H, H-6), 3.74 (s, 6H, CH₃ CO₂Me), 3.54–3.72 (m, 9H, H-2''', H-3', H-4, H-4''', H-5, H-5'', H-5''', H-6'', CH₂), 3.40–3.50 (m, 3H, H-2'', H-4'', CH₂), 3.37 (dd, 1H, J = 3.4, 10.2 Hz, H-2), 3.28 (bt, 2H, J = 5.6 Hz, CH₂), 3.17 (dd, 1H, J = 3.5, 9.5 Hz, H-3'''), 1.52–1.68 (m, 4H, CH₂), 1.32–1.40 (m, 2H, CH₂), 0.88 (s, 9H, CH₃tBu), 0.20 (s, 3H, CH₃ Me), 0.02 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC) δ 167.7, 167.2 (C=O CO₂Me), 156.4 (d, J = 50 Hz, C=O Z), 138.5, 138.4, 137.9, 137.8 (C_q), 136.7 (d, J = 23 Hz, C_q Bn), 128.5, 128.5, 128.3, 128.2, 128.0, 127.9, 127.8, 127.6 (CH_{arom}), 100.6 (C-1'), 100.6 (C-1''), 100.2 (C-1'''), 98.2 (C-1'), 97.0 (C-1), 83.8 (C-3), 81.1 (C-3''), 79.7 (C-2''), 77.5 (C-5'''), 76.2 (C-5'), 75.8 (C-4''), 75.4, 74.5 (CH₂ Bn), 74.1 (C-4'), 73.5 (CH₂ Bn), 71.3, 71.0 (C-4, C-5''), 69.6 (C-5), 67.9 (CH₂), 67.7 (C-4'''), 67.4 (C-6''), 67.1 (CH₂ Z), 64.9 (C-3'''), 62.7 (C-3'), 62.4 (C-2'''), 62.4 (C-6), 62.1, 62.0 (C-2, C-2'), 53.2, 52.4 (CH₃ CO₂Me), 50.3 (d, J = 20 Hz, CH₂ Bn), 46.4 (d, J = 111 Hz, CH₂), 28.8 (CH₂), 28.0 (d, J = 51 Hz, CH₂), 25.5 (CH₃tBu), 23.2 (CH₂), 17.9 (C_qtBu), –4.7, –5.2 (CH₃Me); ¹³C-GATED

(CDCl₃, 100 MHz) δ 100.6 (J_{C1,H1} = 162 Hz, C-1'), 100.2 (J_{C1,H1} = 160 Hz, C-1'''), 98.2 (J_{C1,H1} = 171 Hz, C-1''), 97.0 (J_{C1,H1} = 169 Hz, C-1). The 4'''-OTBS-protected intermediate (84 mg, 55 μmol) was dissolved in THF (0.5 mL) and treated with acetic acid (13 μL, 0.22 mmol) and tetrabutylammonium fluoride (1 M solution in THF, 0.17 mL, 0.17 mmol) at 0 °C. The resulting mixture was stirred at rt for 2 days, after which time H₂O and EtOAc were added. The organic phase was washed with saturated aqueous NaCl (2×), dried over Na₂SO₄, and concentrated in vacuo. Purification using flash column chromatography (silica gel, 75% EtOAc in PE) yielded the title compound as a colorless foam (60 mg, 42 μmol, 75%): TLC R_f 0.31 (PE/EtOAc, 1/2, v/v); [α]_D²⁰ +28.1 (c 1, DCM); IR (neat, cm⁻¹) 698, 731, 1028, 1070, 1683, 1749, 2102, 2927, 3495; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, T = 328 K) δ 7.14–7.39 (m, 25H, CH_{arom}), 5.17 (s, 2H, CH₂ Z), 5.07 (d, 1H, J = 3.4 Hz, H-1''), 4.95 (d, 1H, J = 11.1 Hz, CHH Bn), 4.89 (d, 1H, J = 0.9 Hz, H-1'), 4.83–4.87 (m, 2H, CHH Bn, H-1), 4.76 (d, 1H, J = 11.2 Hz, CHH Bn), 4.73 (d, 1H, J = 11.9 Hz, CHH Bn), 4.67 (d, 1H, J = 11.8 Hz, CHH Bn), 4.60 (d, 1H, J = 11.8 Hz, CHH Bn), 4.50 (s, 2H, CH₂ Bn), 4.31 (s, 1H, H-1'''), 4.16 (t, 1H, J = 8.6 Hz, H-4'), 4.06–4.10 (m, 2H, H-2', H-5'), 4.02 (t, 1H, J = 9.5 Hz, H-4'''), 3.96–4.01 (m, 1H, H-6''), 3.83–3.95 (m, 3H, H-3, H-3'', H-6), 3.77–3.80 (m, 4H, H-6, CH₃ CO₂Me), 3.75 (s, 3H, CH₃ CO₂Me), 3.63–3.72 (m, 5H, H-2''', H-5, H-5'', H-5''', H-6''), 3.53–3.62 (m, 3H, H-3', H-4, CH₂), 3.38–3.47 (m, 3H, H-2'', H-4'', CH₂), 3.35 (dd, 1H, J = 3.4, 7.1 Hz, H-2), 3.33 (dd, 1H, J = 3.3, 6.7 Hz, H-3'''), 3.26 (bt, 2H, J = 5.7 Hz, CH₂), 1.52–1.65 (m, 4H, CH₂), 1.30–1.40 (m, 2H, CH₂); ¹³C-APT NMR (CDCl₃, 100 MHz, HSQC, tentatively assigned based on ¹³C-APT NMR of compound 45) δ 169.4, 167.5 (C=O CO₂Me), 156.5 (d, J = 50 Hz, C=O Z), 138.5, 138.4, 137.9, 137.8 (C_q Bn), 136.7 (d, J = 31 Hz, C_q Bn), 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.6 (CH_{arom}), 100.6 (C-1'), 100.1 (C-1'''), 98.2 (C-1''), 97.0 (C-1), 83.7 (C-3), 81.2 (C-3''), 79.6 (C-2''), 76.1 (C-4'', C-5'), 75.5 (CH₂ Bn), 74.8 (C-5'''), 74.5 (CH₂ Bn), 73.9 (C-4'), 73.6 (CH₂ Bn), 71.0 (C-5, C-5''), 69.7 (C-4), 68.0 (C-6''), 67.8 (d, J = 9 Hz, CH₂), 67.4 (C-4'''), 67.2 (CH₂ Z), 62.7 (C-3'), 62.5 (C-6), 62.4 (C-3'''), 62.2 (C-2, C-3'), 61.9 (C-2', C-2'''), 53.2, 52.8 (CH₃ CO₂Me), 50.3 (d, J = 18 Hz, CH₂ Bn), 46.5 (d, J = 114 Hz, CH₂), 28.9 (CH₂), 27.5 (d, J = 50 Hz, CH₂), 23.2 (CH₂); ¹³C-GATED (CDCl₃, 100 MHz) δ 100.6 (J_{C1,H1} = 162 Hz, C-1'), 100.1 (J_{C1,H1} = 159 Hz, H-1'''), 98.2 (J_{C1,H1} = 166 Hz, C-1''), 97.0 (J_{C1,H1} = 169 Hz, C-1); HRMS [M + NH₄]⁺ calcd for C₆₇H₈₂N₁₇O₂₀ 1444.59165, found 1444.59310.

5-Aminopentyl 3-O-(4-O-[6-O-{2,3-Di-N-acetamido-2,3-dideoxy-β-D-mannopyranosyl Uronate}-α-D-glucopyranosyl]-2,3-di-N-acetamido-2,3-dideoxy-β-D-mannopyranosyl Uronate)-2-N-acetamido-2-deoxy-α-D-glucopyranoside (47). Compound 46 (85 mg, 60 μmol) was dissolved in THF (1 mL) and treated with a freshly prepared solution of aqueous KOOH (0.36 mL, 0.5 M, KOH/H₂O₂ = 1:2) at 0 °C. The resulting solution was stirred at +4 °C overnight, after which time the mixture was neutralized by the addition of 1 M aqueous HCl (pH ~7). EtOAc was added, and the organic phase was washed with saturated aqueous NaCl (2×). The combined aqueous layers were extracted with EtOAc (1×), and the organic fractions were together dried over Na₂SO₄ and concentrated in vacuo to give the crude diacid as a colorless oil (83 mg, 59 μmol): TLC R_f 0.09 (EtOAc/MeOH, 9/1, v/v + 1% AcOH); [α]_D²⁰ +42.0 (c 0.2, DCM); IR (neat, cm⁻¹) 698, 735, 1028, 1072, 1605, 1694, 2106, 2924, 3437. The presence of two uronic acid moieties resulted in such broadening of the NMR signals that accurate assignment was impossible; however, the disappearance of the CO₂Me-signals was confirmed: HRMS [M + H]⁺ calcd for C₆₅H₇₅N₁₆O₂₀ 1399.53380, found 1399.53576. The crude diacid (~83 mg) was dissolved in THF/acetic acid (6 mL, 4/1, v/v) and treated with zinc dust (0.29 g, 4.43 mmol) overnight. Full conversion to the free amine-containing product was verified using LC-MS (R_t = 6.91 min, 10% → 90% B in C). The mixture was subsequently filtrated over a Whatmann filter-containing glass-filter funnel using DCM/MeOH, and the

filtrate was concentrated in vacuo. The residue was dissolved in THF/H₂O (4 mL, 1/1), and the mixture was basified by the addition of solid NaHCO₃ (pH > 8). Acetic anhydride (0.11 mL, 1.18 mmol) was added, and the reaction was allowed to stir at rt until LC-MS analysis indicated complete conversion to the penta-*N*-acetamido intermediate ($R_t = 9.00$ min, 10% → 90% B in C). The mixture was diluted with DCM, washed with saturated aqueous NaCl (1×), dried over Na₂SO₄, and concentrated in vacuo. The residue was dissolved in THF/H₂O (4 mL, 1/1) and treated with 0.45 M aqueous KOH (0.13 mL) to remove any *O*-acetyls. The mixture was then acidified by the addition of 1 M aqueous HCl (pH < 5) and purged with argon. Palladium on activated charcoal (10 wt %, ~20 mg) was added, and the resulting suspension was consecutively purged with argon and H₂(g). The mixture was allowed to stir at rt under a blanket of H₂. When analysis by LC-MS indicated no further conversion to the product, extra palladium black was added and H₂ was again applied. Subsequently, the mixture was filtered through a Whatmann filter-containing glass-filter funnel, neutralized by the addition of saturated aqueous NaHCO₃, and concentrated in vacuo. Purification using HPLC and lyophilization resulted in the title compound as a white fluffy solid (12 mg, 12 μmol, 20% over five steps): ¹H NMR (D₂O, 600 MHz, HH-COSY, HSQC, $T = 313$ K) δ 5.25 (d, 1H, $J = 3.5$ Hz, H-1''), 5.09 (s, 1H, H-1_{Man}), 5.04 (s, 1H, H-1_{Man}), 4.97 (d, 1H, $J = 3.0$ Hz, H-1), 4.63 (d, 1H, $J = 2.3$ Hz, H-2_{Man}), 4.42–4.47 (m, 2H, H-2_{Man}, H-3_{Man}), 4.22 (dd, 1H, $J = 3.5, 10.6$ Hz, H-3_{Man}), 4.12–4.18 (m, 2H, H-2, H-6''), 4.04–4.08 (m, 3H, H-4_{Man}, H-5_{Man}, H-6''), 3.97–4.04 (m, 3H, H-3, H-5_{Man}, H-6), 3.88–3.95 (m, 2H, H-5'', H-6), 3.79–3.87 (m, 3H, H-4_{Man}, H-5, CHH O-CH₂), 3.74 (t, 1H, $J = 10.7$ Hz, H-3''), 3.70 (t, 1H, $J = 9.5$ Hz, H-4), 3.63–3.67 (m, 1H, CHH O-CH₂), 3.59 (t, 1H, $J = 9.6$ Hz, H-4''), 3.53 (dd, 1H, $J = 3.6, 9.8$ Hz, H-2''), 3.17 (t, 2H, $J = 7.4$ Hz, CH₂-NH₂), 2.21 (s, 3H, CH₃ Ac), 2.21 (s, 3H, CH₃ Ac), 2.19 (s, 3H, CH₃ Ac), 2.11 (s, 3H, CH₃ Ac), 2.09 (s, 3H, CH₃ Ac), 1.74–1.88 (m, 4H, CH₂), 1.56–1.67 (m, 2H, CH₂); ¹³C-APT NMR (D₂O, 150 MHz, HSQC) δ 176.7, 176.1, 175.7, 175.7, 175.4, 175.2, 175.1 (C=O Ac, COOH), 100.8 (C-1_{Man}), 100.5 (C-1_{Man}), 99.5 (C-1''), 97.9 (C-1), 82.2 (C-3), 79.5 (C-5_{Man}, C-5_{Man}), 73.5 (C-3''), 72.7 (C-5), 72.4 (C-4_{Man}), 72.2 (C-2''), 71.8 (C-5''), 69.6 (C-4), 69.5 (C-4''), 68.7 (C-6''), 68.6 (O-CH₂), 67.5 (C-4_{Man}), 61.5 (C-6), 54.5 (C-3_{Man}), 54.4 (C-3_{Man}), 53.3 (C-2), 52.6 (C-2_{Man}), 51.9 (C-2_{Man}), 40.4 (CH₂-NH₂), 29.1, 27.5, 23.5 (CH₂), 22.9, 22.8, 22.7 (CH₃ Ac); ¹³C-HMBC (D₂O, 150 MHz) δ 100.8 ($J_{C1,H1} = 162$ Hz, C-1_{Man}), 100.5 ($J_{C1,H1} = 164$ Hz, C-1_{Man}), 99.5 ($J_{C1,H1} = 171$ Hz, C-1''), 97.9 ($J_{C1,H1} = 172$ Hz, C-1); HRMS [$M + H$]⁺ calcd for C₃₉H₆₅N₆O₂₃ 985.40956, found 985.41023.

ASSOCIATED CONTENT

Supporting Information. NMR spectra of low-temperature experiments and all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: marel_g@chem.leidenuniv.nl; jcodee@chem.leidenuniv.nl.

ACKNOWLEDGMENT

We thank C. Erkelens and F. Lefeber for their assistance with executing the NMR experiments. This research was supported by Top Institute Pharma and The Netherlands Organization of Scientific Research (NWO, Vidi grant). We thank Joris van Dam for the journal cover art.

REFERENCES

(1) (a) van den Bos, L. J.; Dinkelaar, J.; Overkleef, H. S.; van der Marel, G. A. *J. Am. Chem. Soc.* **2006**, *128*, 13066–13067. (b) Codée, J. D. C.;

van den Bos, L. J.; de Jong, A.-R.; Dinkelaar, J.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A. *J. Org. Chem.* **2009**, *74*, 38–47. (c) Dinkelaar, J.; de Jong, A.-R.; van Meer, R.; Somers, M.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Org. Chem.* **2009**, *74*, 4982–4991.

(2) (a) Crich, D.; Sun, S. *J. Org. Chem.* **1996**, *61*, 4506–4507. (b) Crich, D.; Sun, S. *Tetrahedron* **1998**, *54*, 8321–8348. (c) Crich, D.; Smith, M. *Org. Lett.* **2000**, *2*, 4067–4069. (d) Crich, D. *Acc. Chem. Res.* **2010**, *43*, 1144–1153.

(3) (a) Walvoort, M. T. C.; Lodder, G.; Mazurek, J.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Am. Chem. Soc.* **2009**, *131*, 12080–12081. (b) Walvoort, M. T. C.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Org. Chem.* **2010**, *75*, 7990–8002.

(4) For reviews on oxacarbenium ion intermediates, see: (a) Walvoort, M. T. C.; Dinkelaar, J.; van den Bos, L. J.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *Carbohydr. Res.* **2010**, *345*, 1252–1263. (b) Smith, D. M.; Woerpel, K. A. *Org. Biomol. Chem.* **2006**, *4*, 1195–1201. (c) Horenstein, N. A. *Adv. Phys. Org. Chem.* **2006**, *41*, 275–314. (d) Bohé, L.; Crich, D. C. R. *Chimie* **2011**, *14*, 3–16.

(5) (a) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125*, 15521–15528. (b) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *122*, 168–169. (c) Lucero, C. G.; Woerpel, K. A. *J. Org. Chem.* **2006**, *71*, 2641–2647.

(6) (a) Crich, D.; Li, L. *J. Org. Chem.* **2007**, *72*, 1681–1690. (b) Crich, D.; Jayalath, P.; Hutton, T. K. *J. Org. Chem.* **2006**, *71*, 3064–3070.

(7) (a) Litjens, R. E. J. N.; Leeuwenburgh, M. A.; Overkleef, H. S.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron Lett.* **2001**, *42*, 8693–8696. (b) Codée, J. D. C.; Litjens, R. E. J. N.; den Heeten, R.; Overkleef, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5*, 1519–1522. (c) Litjens, R. E. J. N.; van den Bos, L. J.; Codée, J. D. C.; van den Berg, R. J. B. H. N.; Overkleef, H. S.; van der Marel, G. A. *Eur. J. Org. Chem.* **2005**, 918–924.

(8) Szurmai, Z.; Rákó, J.; Ágoston, K.; Danan, A.; Charon, D. *Org. Lett.* **2000**, *2*, 1839–1842.

(9) (a) Schäffer, C.; Messner, P. *Microbiology* **2005**, *151*, 643–651. (b) Knirel, Y. A.; Vinogradov, E. V.; Shashkov, A. S.; Dmitriev, B. A.; Kochetkov, N. K. *Carbohydr. Res.* **1982**, *104*, C4–C7.

(10) (a) Messner, P.; Sleytr, U. B.; Christian, R.; Schulz, G.; Unger, F. M. *Carbohydr. Res.* **1987**, *168*, 211–218. (b) Schäffer, C.; Kählig, H.; Christian, R.; Schultz, G.; Zayni, S.; Messner, P. *Microbiology* **1999**, *145*, 1575–1583.

(11) van den Bos, L. J.; Duivenvoorden, B. A.; de Koning, M. C.; Filippov, D. V.; Overkleef, H. S.; van der Marel, G. A. *Eur. J. Org. Chem.* **2007**, 116–124.

(12) Baek, J. Y.; Lee, B.-Y.; Jo, M. G.; Kim, K. S. *J. Am. Chem. Soc.* **2009**, *131*, 17705–17713.

(13) (a) Guthrie, R. D.; Murphy, D. *J. Chem. Soc.* **1965**, 6956–6960. (b) Kok, G. B.; Campbell, M.; Mackey, B. L.; von Itzstein, M. *Carbohydr. Res.* **2001**, *332*, 133–139. (c) Nilsson, M.; Norberg, T. *Carbohydr. Res.* **2000**, *327*, 261–267.

(14) Evans, M. E. *Carbohydr. Res.* **1972**, *21*, 473–475.

(15) As reported earlier, the byproduct resulting from β-elimination between C-3 and C-4 was also observed (approx. 10%). It was easily removed from the product by flash column chromatography. Krist, P.; Kuzma, M.; Pelyvás, I. F.; Simerská, P.; Křen, V. *Collect. Czech. Chem. Commun.* **2003**, *68*, 801–811.

(16) De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. *J. Org. Chem.* **1997**, *62*, 6974–6977.

(17) (a) van den Bos, L. J.; Codée, J. D. C.; van der Toorn, J. C.; Boltje, T. J.; van Boom, J. H.; Overkleef, H. S.; van der Marel, G. A. *Org. Lett.* **2004**, *6*, 2165–2168. (b) Walvoort, M. T. C.; Sail, D.; van der Marel, G. A.; Codée, J. D. C. *Carbohydrate Chemistry: Proven Methods*; CRC Press: Boca Raton, FL, 2011; Vol. 1, Chapter 11, p 99.

(18) (a) Codée, J. D. C.; van den Bos, L. J.; Litjens, R. E. J. N.; Overkleef, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5*, 1947–1950. (b) van den Bos, L. J.; Litjens, R. E. J. N.; van den Berg, R. J. B. H. N.; Overkleef, H. S.; van der Marel, G. A. *Org. Lett.* **2005**, *7*, 2007–2010. (c) Codée, J. D. C.; Boltje, T. J.; van der Marel, G. A. *Carbohydrate Chemistry: Proven Methods*; CRC Press: Boca Raton, FL, 2011; Vol. 1, Chapter 6, p 67.

- (19) (a) Garcia, B. A.; Poole, J. L.; Gin, D. Y. *J. Am. Chem. Soc.* **1997**, *119*, 7597–7598. (b) Garcia, B. A.; Gin, D. Y. *J. Am. Chem. Soc.* **2000**, *122*, 4269–4279.
- (20) In the case of benzylidene donor 7, TTBP (75 μmol) was added.
- (21) Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91*, 165–195.
- (22) Crich, D.; Xu, H. *J. Org. Chem.* **2007**, *72*, 5183–5192.
- (23) (a) Crich, D.; Vinogradova, O. *J. Org. Chem.* **2006**, *71*, 8473–8480. (b) Crich, D.; Xu, H. *J. Org. Chem.* **2007**, *72*, 5183–5192.
- (24) Eliel, E. L.; Wilen, S. H. *Stereochemistry of Organic Compounds*; John Wiley & Sons: New York, 1994.
- (25) See for a review on glycosyl donors in “unusual” conformations: Pedersen, C. M.; Marinescu, L. G.; Bols, M. C. R. *Chimie* **2011**, *14*, 17–43.
- (26) (a) Vasella, A.; Witzig, C.; Chiara, J. L.; Martín Lomas, M. *Helv. Chim. Acta* **1991**, *74*, 2073–2077. (b) Alper, P. B.; Hung, S. C.; Wong, C.-H. *Tetrahedron Lett.* **1996**, *37*, 6029–6032. (c) Yu, B.; Tao, H. *Tetrahedron Lett.* **2001**, *42*, 2405–2407.
- (27) Park, J.; Kawatkar, S.; Kim, J.-H.; Boons, G.-J. *Org. Lett.* **2007**, *9*, 1959–1962.
- (28) (a) Adinolfi, M.; Barone, G.; Iadonisi, A.; Shiattarella, M. *Tetrahedron Lett.* **2002**, *43*, 5573–5577. (b) Adinolfi, M.; Iadonisi, A.; Schiattarella, M. *Tetrahedron Lett.* **2003**, *44*, 6479–6482.
- (29) Nelson, T. D.; Crouch, R. D. *Synthesis* **1996**, 1031–1069.
- (30) Amantini, D.; Fringuelli, F.; Vaccaro, L. *Org. Prep. Proc.* **2002**, *34*, 109–147.
- (31) Larkin, A.; Olivier, N. B.; Imperiali, B. *Biochemistry* **2010**, *49*, 7227–7237.
- (32) Rauter, A. P.; Oliveira, O.; Canda, T.; Leroi, E.; Ferreira, H.; Ferreira, M. J.; Ascenso, J. A. *J. Carbohydr. Chem.* **2002**, *21*, 257–273.
- (33) Raaijmakers, H. W. C.; Zwanenburg, B.; Chittenden, G. J. F. *Carbohydr. Res.* **1993**, *238*, 185–192.
- (34) Tamura, K.; Mizukami, H.; Maeda, K.; Watanabe, H.; Uneyama, K. *J. Org. Chem.* **1993**, *58*, 32–35.